

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058075
Article Type:	Original research
Date Submitted by the Author:	07-Oct-2021
Complete List of Authors:	<p>Yuan, Haoyong; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Wu, Zhongshi; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Lu, Ting; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Wei, Tingting; Hunan Provincial Maternal and Child Health Care Hospital, Department of Paediatrics</p> <p>Zeng, Yifan; Central South University, Department of Cardiovascular Surgery</p> <p>Liu, Yalin; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Huang, Can; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p>
Keywords:	Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Myocardial infarction < CARDIOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Comparison of biodegradable and durable polymer drug-eluting stents in**  
5  
6  
7 **acute coronary syndrome**  
8

9  
10 Haoyong Yuan, MD<sup>1,2</sup>, Zhongshi Wu, MD<sup>1,2</sup>, Ting Lu, MD<sup>1,2</sup>, Tingting Wei, MD<sup>3</sup>, Yifan  
11  
12 Zeng, MD<sup>1</sup>, Yalin Liu<sup>1,2</sup>, Can Huang, MD<sup>1,2\*</sup>  
13  
14

15  
16 <sup>1</sup>Department of Cardiovascular Surgery, the Second Xiangya Hospital, Central South  
17  
18 University, Changsha, Hunan 410011, China  
19

20  
21 <sup>2</sup>Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials, Changsha,  
22  
23 Hunan 410008, China  
24  
25

26  
27 <sup>3</sup>Department of Paediatrics, Hunan Provincial Maternal and Child Health Care Hospital,  
28  
29 Changsha, Hunan 410008, China  
30  
31

32  
33  
34  
35  
36 **\*Corresponding author:** Can Huang  
37

38  
39 Department of Cardiovascular Surgery, Second Xiangya Hospital, Central South University,  
40  
41 #139 Renmin Road, Changsha, Hunan, 410011, P.R. China  
42

43  
44 Tel: +86 73185292133  
45

46  
47 Fax: +86 73185292133  
48

49  
50 E-mail: huangcan413@csu.edu.cn  
51

52  
53 Word count: 2968  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Purpose:** To compare the safety and effectiveness between biodegradable (BP-DES) and durable polymer drug-eluting stents (DP-DES) in acute coronary syndrome (ACS) patients.

**Methods:** We searched PubMed, Medline, Embase, and the Cochrane Controlled Register of Trials (CENTRAL) for comparative studies of BP-DES versus DP-DES in patients with ACS, from January 2000 to July 2021. Statistical pooling was performed for estimating incidence, using a random-effects model with generic inverse-variance weighting. Risk estimates were computed with 95% confidence intervals (CIs), using RevMan 5.3.

**Results:** Nine articles that compared BP-DES and DP-DES in ACS patients were identified and included in qualitative and quantitative analyses. There was no difference in the baseline characteristics, except for the total stent length, which was longer in the BP-DES group. A pooled analysis demonstrated that major cardiac adverse events, efficacy endpoints, and safety endpoints were similar between the 2 groups at 1 year. However, the total stent thrombosis (ST) incidence was significantly different between the BP-DES and DP-DES groups in the follow-up period. Subgroup analysis showed a statistically significant difference in the total ST, MACE, TLR, TVR and ST incidence over 2 years.

**Conclusion:** This meta-analysis revealed that the 2 stent types showed excellent safety and efficacy profiles at 12 months. However, there was a slightly increased MACE, TLR, TVR and ST incidence in the DP-DES group over the 2-year follow-up period, suggesting that BP-DES may be more favourable for treating patients with ACS.

**Keywords:** acute coronary syndrome, biodegradable drug-eluting stent, durable polymer

1  
2  
3  
4 drug-eluting stent, major adverse cardiac event, stent thrombosis, target lesion  
5  
6  
7 revascularization, target vessel revascularization  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### **Strengths and limitations of this study**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1) This is the first meta analysis comparing the clinical outcomes of the two polymer in the patients with acute coronary syndrome. 2) In this meta-analysis, the research rolling in are all RCT and the follow up are all over 1 year even for 5 years, so the result maybe convincing. 3) According to the data, we suggest that both polymer types showed excellent safety and efficacy profiles at 1 year and BP-DES may be more favourable for treating patients with ACS due to a slightly increased incidence of MACE, TLR, TVR and ST in the DP-DES group in the follow-up period over 2 years.

However, the analysis maybe has some limitations. The present study had several limitations, which may introduce some bias. First, this study included RCTs and shares the limitations of original studies. Second, Biodegradable polymer DES are a heterogeneous group of stents differing with regards to stent platform thickness, time to complete degradation of the polymer, and drug-elution kinetics. The comparator group of durable polymer DES is an equally heterogeneous group. We were unable to match the stents in regards to the strut thickness and drug. As a consequence, the reported results may not be generalizable to all stents from the respective group. Third, Over 6 month dual antiplatelet therapy was given to the patients rolling in our including RCT trails, the difference of the duration of dual antiplatelet therapy that may influence the clinical outcomes.

***No additional data available***

### ***Patient and public involvement***

We do not need the patient and public involvement, as this is a meta analysis and no new patients were rolled in it.

### **Contributorship Statement**

Can Huang, Zhongshi Wu, and Haoyong Yuan developed the idea of the study, participated in its design and coordination and helped to draft the manuscript. Ting Lu and Tingting Wei contributed to the acquisition and interpretation of data. Yifan Zeng and Yalin Liu provided critical review and substantially revised the manuscript. All authors read and approved the final manuscript.

### **Ethics approval**

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the protocol was registered with PROSPERO (CRD42021253412). This study was approved by the institutional review board of the Second Xiangya Hospital, Central South University.

### **Funding**

This work was supported by Hunan Provincial Natural Science Foundation of China, grant number(2020JJ4787).



## Introduction

Percutaneous coronary intervention (PCI) is the current standard of care for patients with coronary artery disease, particularly acute coronary syndrome (ACS)(1, 2). Unlike bare-metal stents (BMS), drug-eluting stents (DES) use antiproliferative agents embedded in a polymer coating on the stent's surface, which inhibit neointimal hyperplasia to reduce the risk of restenosis(3). Although DES have substantially improved clinical outcomes, the first-generation durable polymer DES (DP-DES) released sirolimus or paclitaxel, and were associated with similar risks of death and myocardial infarction as BMS beyond 1 year after implantation(4). Later, the second-generation DP-DES were confirmed to have lower restenosis rates than first-generation devices and showed reduced rates of stent thrombosis (ST)(5). Recently, very late ST and neoatherosclerosis, with adverse clinical outcomes, have been observed with second-generation DP-DES, which has improved the biocompatibility of the polymer(6). Late stent failure has been attributed to delayed endothelial healing secondary to a hypersensitivity reaction to the durable polymer(7).

To address this potential limitation of DP-DES, biodegradable polymer DES (BP-DES) have been developed. Theoretically, BP-DES would lead to a reduction in vascular inflammation and a decreased risk of late stent-related complications due to the advantage of leaving behind only the BMS after complete drug elution and polymer degradation. BP-DES have been observed to reduce the rate of major adverse cardiac events (MACEs) compared to BMS(8) and first-generation DP-DES(9). Studies of all-comers who underwent PCI showed that the device-related outcomes were comparable between BP-DES and second-generation DP-DES(10-13). Thus, BP-DES would be expected to reduce the risk of ST-related MACEs

1  
2  
3  
4 beyond the first year, as compared to DP-DES. However, previous studies enrolled a  
5  
6 significant proportion of stable angina patients. ACS confers an increased risk of adverse  
7  
8 outcome due to plaque characteristics, including culprit lesions, thrombus burden, and  
9  
10 persistent inflammation, compared to stable coronary artery diseases. ACS would also  
11  
12 increase the risk of delayed arterial healing and vessel remodelling(14), reflected by higher  
13  
14 rates of incomplete stent strut coverage(15, 16) and malpositioning(17).  
15  
16  
17  
18  
19

20 Recently, the randomized trials have been performed to compare the efficacy and safety  
21  
22 of DP-DES and BP-DES in an ACS population who underwent PCI. In this meta-analysis, we  
23  
24 aimed to summarize studies comparing the 2 polymer technologies in ACS patients and to  
25  
26 analyse the safety and effectiveness of these therapeutic options.  
27  
28  
29  
30

## 31 **Methods**

### 32 *Search strategy and registration*

33  
34  
35 This study was conducted according to the Preferred Reporting Items for Systematic  
36  
37 Reviews and Meta-Analyses (PRISMA) guidelines. This study was approved by the  
38  
39 institutional review board of the Second Xiangya Hospital, Central South University and the  
40  
41 protocol was registered with PROSPERO (CRD42021253412).  
42  
43  
44  
45  
46  
47  
48

49 Based on the PRISMA statement, PubMed, Medline, Embase, and the Cochrane  
50  
51 Controlled Register of Trials (CENTRAL) databases were searched for comparative studies  
52  
53 of BP-DES versus DP-DES in the treatment of ACS patients who underwent PCI. The  
54  
55 following search terms were used: 'BP-DES', 'DP-DES', 'Acute coronary syndrome', 'Acute  
56  
57 myocardial infarction', 'biodegradable', 'bioabsorbable', 'polymer', 'everolimus',  
58  
59  
60

1  
2  
3  
4 'zotarolimus', 'endeavor', 'Resolute', 'Xience', and 'drug-eluting stent'. We also reviewed  
5  
6 prior meta-analyses and the reference lists of the original trials and review articles to identify  
7  
8 further studies. Only English language articles published in peer-reviewed journals from  
9  
10 January 2000 to July 2021 were selected. Analyses were conducted by 2 independent  
11  
12 reviewers.  
13  
14  
15

### 16 17 ***Eligibility criteria*** 18

19  
20 The inclusion criteria for this meta-analysis were as follows: 1) randomized controlled  
21  
22 trials (RCTs) comparing BP-DES and DP-DES in the treatment of ACS patients who  
23  
24 underwent PCI; 2) studies that reported data on patients' baseline characteristics, follow-up  
25  
26 duration, outcomes at the primary, safety, and efficacy endpoints; 3) studies where the mean  
27  
28 follow-up time was over 12 months; and 4) full-text articles.  
29  
30  
31  
32

33  
34 The exclusion criteria for the meta-analysis were the following: 1) duplicate of the  
35  
36 sample size and reports evaluated by 2 independent reviewers; 2) case reports/series; 3)  
37  
38 studies involving data from a national database.  
39  
40  
41

### 42 43 ***Data extraction and outcome measurement*** 44

45  
46 Two authors (Haoyong Yuan and Tingting Wei) systematically screened the titles and  
47  
48 abstracts of publications retrieved using the search strategy to select studies that met the  
49  
50 above inclusion criteria. Any disagreement between them over the eligibility of particular  
51  
52 studies was resolved through discussion and involvement of a third author (Zhongshi Wu),  
53  
54 when necessary. First, baseline characteristics, including the name of the first author, year of  
55  
56 publication, study design, country of origin, number of patients, mean age of subjects, and  
57  
58  
59  
60

1  
2  
3  
4 mean duration of follow-up were gathered from each included article. In addition, sex; body  
5  
6 mass index; the presence of hypertension, diabetes, dyslipidaemia, chronic kidney disease,  
7  
8 peripheral vessel disease, or smoking; left ventricular ejection fraction (LVEF), number of  
9  
10 stents per person, and total stent length were collected for evaluation of procedure risk.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

MACEs were considered as the primary endpoint. The efficacy endpoint included target vessel revascularization (TVR) and target lesion revascularization (TLR). In addition, all-cause death, cardiac death, target vessel myocardial infarction (TVMI), and ST were employed as the safety endpoints to evaluate the safety of BP-DES and DP-DES.

Quality assessment of RCTs was based on sequence generation; randomized group allocation; concealment; blinding of participants, personnel, and outcome assessors; incomplete data; selectivity; outcome reporting, and other sources of bias

### ***Data analysis and synthesis***

Continuous variables are reported as the mean (standard deviation) and categorical variables are expressed as number. Statistical pooling was performed to estimate incidence, according to a random-effects model with generic inverse-variance weighting. We computed risk estimates with 95% confidence intervals (CIs), using RevMan 5.3 (The Cochrane Collaboration, The NordicCochrane Centre, Copenhagen, Denmark). Hypothesis testing for superiority was set at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and was based on the Cochran Q test, with  $I^2$  values of 25%, 50%, and 75% representing mild, moderate, and severe heterogeneity, respectively.

### **Results**

### ***Search results***

A total of 895 articles, written in English, were identified through the literature search. After an initial screening of the titles and abstracts, articles were eliminated, as they were not related to the topic of this study. 92 clinical studies and RCT articles of the two polymers remained. After further reading the full text, 28 articles about acute coronary syndromes were left and the patients of the 20 articles include the chronic and acute coronary syndrome. Finally, 8 articles of randomized controlled trials comparing BP-DES and DP-DES in patients with ACS were identified and were included in the qualitative and quantitative analyses (18-25). The follow-up duration ranged from 1 year to 5 years (Table 1).

### ***General features of the trials***

A total number of 8089 patients (3898 patients who were treated with BP-DES and 4191 patients who were treated with the DP-DES) were included in this analysis. Further details about the total number of patients retrieved from each trial, the publication year, the country of origin of the publication, the centre in which trials were performed, the follow-up duration, the risk factors, primary, efficacy, and safety endpoints are listed in Table 1 to Table 3.

### ***Patient characteristics***

The baseline features of the patients are summarized in Tables 2. The mean age of the patients who were treated by BP-DES ranged from 61.3 to 64 years old, whereas the mean age of the patients who were treated by DP-DES ranged from 61.7 to 64.1 years. The number of male patients were above 70% in all the included trials. There was no difference in age

(mean difference [MD]: 0.14, 95%CI: -0.66–0.38; P = 0.60,  $I^2 = 0\%$ ), sex (male) (odds ratio [OR]: 1.10, 95%CI: 0.99–1.23; P = 0.07,  $I^2 = 0\%$ ), hypertension (OR: 1.03, 95%CI: 0.94–1.13; P = 0.57,  $I^2 = 37\%$ ), dyslipidaemia (OR: 0.92, 95%CI: 0.83–1.02; P = 0.10,  $I^2 = 36\%$ ), LVEF (MD: 0.00, 95%CI: 0.00–0.01; P = 0.12  $I^2 = 12\%$ ), body mass index (MD:0.07, 95%CI: -0.11 to 0.25; P = 0.44,  $I^2 = 0\%$ ), diabetes (OR: 0.92, 95%CI: 0.83–1.02; P = 0.13,  $I^2 = 21\%$ ), total stent length (MD: -0.72, 95%CI: -2.30 to -0.85; P = 0.37,  $I^2 = 40\%$ ), and number of stents per person (MD: -0.00, 95%CI: -0.05 to 0.04; P = 0.84,  $I^2 = 0\%$ ) among patients who were implanted with BP-DES or DP-DES. A pooled analysis demonstrated that the number of smoking patients (OR: 1.13, 95%CI: 1.03–1.24; P = 0.008  $I^2 = 29\%$ ) is significantly lower in the BP-DES group than in the DP-DES group (Fig. 1 A–C).

***Primary endpoint: MACEs reported during a follow-up period of 1–5 years, 1 year, and over 2 years***

MACEs, including all-cause death, recurrent MI, or any coronary repeat revascularization involving TLR, TVR, and non-TVR, were considered as the primary endpoint of the trials. A pooled analysis indicated no statistically significant difference in MACEs in a follow-up period ranging from 1 to 5 years between the 2 groups (OR: 0.87, 95%CI: 0.75–1.01; P = 0.07,  $I^2 = 50\%$ ). Of the 5 studies that published 1-year outcomes, MACEs were not significantly different between the BP-DES and DP-DES groups, with OR: 0.97, 95%CI: 0.81–1.16; P = 0.74,  $I^2 = 44\%$ . However, the over 2-year MACE is significant lower in the BP-DES group with OR: 0.71, 95%CI: 0.57–0.88; P = 0.002,  $I^2 = 0\%$  (Fig. 2).

1  
2  
3  
4 ***Efficacy endpoint: TVR and TLR reported during a follow-up period of 1–5 years, 1 year,***  
5  
6 ***and over 2 years***  
7  
8  
9

10 TLR and TVR were considered as the efficacy endpoints of the trials. A pooled analysis  
11 indicated no statistically significant difference in TLR in a follow-up period ranging from 1  
12 to 5 years between the 2 groups (OR: 0.78, 95%CI: 0.61–1.00; P = 0.05,  $I^2 = 48\%$ ). Among  
13 the 5 studies that published 1-year data, TLR was not significantly different between the  
14 BP-DES and DP-DES groups with OR: 0.72, 95%CI: 0.40–1.31; P = 0.29,  $I^2 = 65\%$ . A  
15 pooled analysis indicated no statistically significant difference in TVR over a follow-up  
16 period ranging from 1 to 5 years, with OR: 1.01, 95%CI: 0.79–1.28; P = 0.96,  $I^2 = 46\%$ , 1  
17 year in 3 publications, with OR: 0.98, 95%CI: 0.40–2.38; P = 0.96,  $I^2 = 76\%$ . However, the  
18 over 2-year TLR in 4 RCT studies, with OR: 0.71, 95%CI: 0.51–1.01; P = 0.05,  $I^2 = 0\%$  and  
19 over 2-year TVR in 3 studies, with OR: 0.70, 95%CI: 0.52–0.94; P = 0.002,  $I^2 = 15\%$  are  
20 much lower in BP group (Figs. 3, 4).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 ***Safety endpoint: All-cause death, cardiac-related death, target vessel myocardial infarction,***  
40 ***and stent thrombosis over a follow-up period of 1–5 years, 1 year, and over 2 years***  
41  
42  
43  
44

45 All-cause death, cardiac-related death, TVMI, and ST were considered as the efficacy  
46 endpoint of the trails. A pooled analysis indicated no statistically significant difference in  
47 all-cause death (OR: 0.88, 95%CI: 0.72–1.07; P = 0.20,  $I^2 = 0\%$ ), cardiac-related death (OR:  
48 0.89, 95%CI: 0.71–1.12; P = 0.32,  $I^2 = 20\%$ ), and TVMI (OR: 0.73, 95%CI: 0.53–1.01; P =  
49 0.05,  $I^2 = 0\%$ ) over a follow-up period ranging from 1 to 5 years, between the 2 groups. Of  
50 the 5 studies that published 1-year data, all-cause death, cardiac-related death, and TVMI  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 were not significantly different between the BP-DES and DP-DES groups (all-cause death  
5  
6 OR: 0.91, 95%CI: 0.71–1.15;  $P = 0.42$ ,  $I^2 = 0\%$ , cardiac-related death OR: 0.96, 95%CI:  
7  
8 0.74–1.26;  $P = 0.79$ ,  $I^2 = 35\%$ , TVMI OR: 0.73, 95%CI: 0.53–1.01;  $P = 0.05$ ,  $I^2 = 0\%$ ).  
9  
10  
11 Similar findings were observed for the over 2-year all-cause cardiac death, cardiac-related  
12  
13 death, and TVMI in 5 studies (all-cause death OR: 0.85, 95%CI: 0.64–1.12;  $P = 0.25$ ,  $I^2 = 0\%$ ,  
14  
15 cardiac-related death OR: 0.77, 95%CI: 0.56–1.17;  $P = 0.12$ ,  $I^2 = 0\%$ , TVMI OR: 0.79,  
16  
17 95%CI: 0.51–1.22;  $P = 0.28$ ,  $I^2 = 0\%$ ), respectively (Figs. 5–7). However, the total ST  
18  
19 incidence, including the definite ST, probable ST, and definite or probable ST incidence, was  
20  
21 significantly different between the BP-DES and DP-DES groups over the follow-up period  
22  
23 (OR: 0.59, 95% CI: 0.46–0.77;  $P = 0.0001$ ,  $I^2 = 48\%$ ). Subgroup analysis revealed no  
24  
25 difference in total ST for a 1-year follow-up (OR: 0.61, 95%CI: 0.32–1.15;  $P = 0.13$ ,  $I^2 =$   
26  
27 72%), while pooled analysis indicated a statistically significant difference in the total ST for  
28  
29 the over 2-year follow-up (OR: 0.63, 95%CI: 0.47–0.85;  $P = 0.002$ ,  $I^2 = 0\%$ ) (Fig. 8).  
30  
31  
32  
33  
34  
35  
36  
37

## 38 Discussion

39  
40  
41 The choice of stent in patients undergoing PCI for ACS is debated. Coronary  
42  
43 intervention with second-generation DP-DES generally reduces the need for revascularisation  
44  
45 and improves mortality, as compared to BMS and first-generation DP-DES. Furthermore, the  
46  
47 risk of late ST with DP-DES tends to off-set the benefit from reduction in the need for  
48  
49 revascularisation in patients with ACS, as seen in real-world registries and clinical trials  
50  
51 comparing them to BMS(15, 26). BP-DES was designed to leave only the BMS behind once  
52  
53 the polymer has bio-degraded completely after drug elution, and may represent an attractive  
54  
55 solution for patients with ACS(27). Prior meta-analyses have compared the clinical outcomes  
56  
57  
58  
59  
60



1  
2  
3  
4 among BMS, DP-DES, and BP-DES in patients with stable coronary artery disease, but no  
5  
6 previous meta-analysis of RCTs and prospective trials directly comparing clinical outcomes  
7  
8 between BP-DES and DP-DES for the treatment of ACS. To our knowledge, this  
9  
10 meta-analysis exclusively compared BP-DES to DP-DES. It included 8 trials representing  
11  
12 8089 patients with a longer follow-up duration, ranging from 1 year to 5 years. Although  
13  
14 BP-DES have been hypothesised to offer improved outcomes, mainly in the long term,  
15  
16 several prior meta-analyses have demonstrated different outcomes with BP-DES as compared  
17  
18 to DP-DES in patients undergoing PCI. Bangalore et al. found that BP-DES were associated  
19  
20 with higher mortality than DP-DES beyond 1 year of follow-up(28). El-Hayek et al.  
21  
22 demonstrated no significant difference in mortality between these types of stent(6). In our  
23  
24 study, there was no significant differences in MACE, all-cause death, cardiac-related death,  
25  
26 TVMI, TVR, or TLR at a follow-up of 1 year and all-cause death, cardiac death, TVMI at a  
27  
28 follow-up of over 2 years. However, the over 2-year MACE, TVR and TLR are significant  
29  
30 lower in the BP group comparing to the DP group. Pilgrim, T found that a higher all cause  
31  
32 mortality among patients treat with BP-SES compared with DP-EES in the BIOSCIENCE  
33  
34 trail, they also think comparable rates of all-cause motality between patients treated with  
35  
36 BP-SES and DP-EES in the BIOSTEMI trail at 2 years(25). Taken together, this suggests that  
37  
38 BP-DES share similar outcomes in terms of MACEs (all-cause death, cardiac-related death,  
39  
40 TVMI, TVR, and TLR during a 1-year follow-up and maybe significant improve clinical  
41  
42 outcomes over 2 years follow up.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55  
56 ST is used to evaluate the safety of the stent. The risk of ST, particularly late ST  
57  
58 occurring beyond 30 days, remains among the major concerns limiting the use of DES in the  
59  
60

1  
2  
3  
4 treatment of ACS(29). Early-generation DP-DES were associated with increased rates of very  
5  
6 late (> 1 year) ST, as compared with BMS. It was hypothesized that the mechanism  
7  
8 underlying late ST with first DP-DES in ACS is related to adverse reactions to the durable  
9  
10 polymer(30), and the use of more biocompatible polymer has been associated with a  
11  
12 reduction in ST in high-risk patients(9). In the LEADERS trial, the rate of very late ST was  
13  
14 lower with the use of the BP-DES than with DP-DES(31). Our data demonstrated that both  
15  
16 BP-DES and DP-DES have similar risks of ST beyond 1 year. However, BP-DES are  
17  
18 associated with a significantly reduced risk of ST at a follow-up of over 2 years as compared  
19  
20 with DP-DES (OR: 0.64, 95%CI: 0.46–0.88; P = 0.006,  $I^2 = 0\%$ ). On the other hand, Kim et  
21  
22 al. found that the incidence of ST by groups showed numerically lower rates in the DP-DES  
23  
24 group (0.1%) than in the BP-DES group, and that all late ST cases occurred in those receiving  
25  
26 thick-strut BP-DES stents. They proposed that no meaningful differences in terms of ST  
27  
28 could be identified between the different polymer technologies by intravascular imaging and  
29  
30 that the association of polymer technology and the risk of the ST was difficult to prove(19, 32,  
31  
32 33). It may therefore be hypothesized that the BP-DES result in improved arterial healing,  
33  
34 which in turn not only minimizes the risk of ST, but also improves the long-term durability of  
35  
36 the antirestenotic efficacy in the long term, even though the 2 groups have a similar risk of  
37  
38 ST beyond 1 year.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 51 **Limitations**

52  
53  
54 The present study had several limitations, which may introduce some bias. First, this  
55  
56 study included RCTs and shares the limitations of original studies. Second, Biodegradable  
57  
58 polymer DES are a heterogeneous group of stents differing with regards to stent platform  
59  
60

1  
2  
3  
4 thickness, time to complete degradation of the polymer, and drug-elution kinetics. The  
5  
6 comparator group of durable polymer DES is an equally heterogeneous group. We were  
7  
8 unable to match the stents in regards to the strut thickness and drug. As a consequence, the  
9  
10 reported results may not be generalizable to all stents from the respective group. Third, Over 6  
11  
12 month dual antiplatelet therapy was given to the patients rolling in our including RCT trails, the  
13  
14 difference of the duration of dual antiplatelet therapy that may influence the clinical outcomes.  
15  
16  
17  
18  
19

## 20 **Conclusion**

21  
22  
23 In this meta-analysis comparing BP-DES to DP-DES in ACS patients who underwent PCI,  
24  
25 the data indicated that both polymer types showed excellent safety and efficacy profiles at 1  
26  
27 year. There was a slightly increased incidence of MACE, TLR, TVR and ST in the DP-DES  
28  
29 group in the follow-up period over 2 years, suggesting that BP-DES may be more favourable  
30  
31 for treating patients with ACS. These findings should be confirmed by the long-term  
32  
33 follow-up in RCT trials.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Table Legends

Table 1. The characteristics of the included trials

Table 2. The baseline features of the patients

## Figure Legends

Fig. 1 A. Baseline characteristics and stent information of patients with acute coronary syndrome

Fig. 1B. Baseline characteristics and stent information of patients with acute coronary syndrome

Fig. 1C. Baseline characteristics and stent information of patients with acute coronary syndrome

Fig. 2. Primary endpoint: major adverse cardiac events

Fig. 3. Target vessel revascularization

Fig. 4. Target lesion revascularization

Fig. 5. All-cause death

Fig. 6. Cardiac-related death

Fig. 7. Target vessel myocardial infarction

Fig. 8. Stent thrombosis

## References:

1. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA*.(2005)293: 2908-17. doi:10.1001/jama.293.23.2908
2. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. *J AM COLL CARDIOL*.(2010)55: 2435-45. doi:10.1016/j.jacc.2010.03.007
3. Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S, Guo L, Mori H, Harari E, Paek KH, Fernandez R, Chahal D, Romero ME, Kolodgie FD, Gupta A, Virmani R, Finn AV. Drug-eluting coronary stents: insights from preclinical and pathology studies. *NAT REV CARDIOL*.(2020)17: 37-51. doi:10.1038/s41569-019-0234-x
4. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. *JAMA*.(2008)299: 1788-99. doi:10.1001/jama.299.15.joc80026
5. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. *CIRCULATION*.(2012)125: 1110-21. doi:10.1161/CIRCULATIONAHA.111.058560

- 1  
2  
3  
4 6.El-Hayek G, Bangalore S, Casso DA, Devireddy C, Jaber W, Kumar G, Mavromatis K, Tamis-Holland J,  
5  
6 Samady H. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting  
7  
8 Stent to Second-Generation Durable Polymer Drug-Eluting Stents. *JACC Cardiovasc Interv.*(2017)10:  
9  
10 462-473. doi:10.1016/j.jcin.2016.12.002  
11  
12  
13  
14  
15 7.Finn AV, Nakazawa G, Kolodgie FD, Virmani R. Temporal course of neointimal formation after  
16  
17 drug-eluting stent placement: is our understanding of restenosis changing? *JACC Cardiovasc Interv.*(2009)2:  
18  
19 300-2. doi:10.1016/j.jcin.2009.01.004  
20  
21  
22  
23  
24 8.Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A,  
25  
26 Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF,  
27  
28 Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable  
29  
30 polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the  
31  
32 COMFORTABLE AMI randomized trial. *JAMA.*(2012)308: 777-87. doi:10.1001/jama.2012.10065  
33  
34  
35  
36  
37 9.Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tsepili M, den  
38  
39 Heijer P, Bethencourt A, Vazquez N, Gomez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso  
40  
41 F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW.  
42  
43 Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction  
44  
45 (EXAMINATION): 1 year results of a randomised controlled trial. *LANCET.*(2012)380: 1482-90.  
46  
47  
48  
49  
50  
51  
52  
53  
54 10.von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin R, Somi S, van  
55  
56 Houwelingen KG, Stoel MG, de Man F, Louwerenburg J, Hartmann M, Zocca P, Linszen G, van der Palen J,  
57  
58 Doggen C, Lowik MM. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting  
59  
60

- 1  
2  
3  
4 stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease  
5  
6 (BIO-RESORT): a three-arm, randomised, non-inferiority trial. *LANCET*.(2016)388: 2607-2617.  
7  
8  
9 doi:10.1016/S0140-6736(16)31920-1  
10  
11  
12 11.Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuillomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi  
13  
14 P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Juni P, Windecker S. Ultrathin strut  
15  
16 biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for  
17  
18 percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.  
19  
20  
21  
22 *LANCET*.(2014)384: 2111-22. doi:10.1016/S0140-6736(14)61038-2  
23  
24  
25  
26 12.Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra  
27  
28 A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus  
29  
30 durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.  
31  
32  
33  
34 *LANCET*.(2013)381: 651-60. doi:10.1016/S0140-6736(12)61852-2  
35  
36  
37 13.Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe  
38  
39 K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K,  
40  
41 Urasawa K, Tarutani Y, Shiode N, Kimura T. Biodegradable polymer biolimus-eluting stent versus durable  
42  
43 polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. *J AM COLL*  
44  
45  
46  
47 *CARDIOL*.(2013)62: 181-190. doi:10.1016/j.jacc.2013.04.045  
48  
49  
50  
51 14.Pilgrim T, Piccolo R, Heg D, Roffi M, Tuller D, Vuillomenet A, Muller O, Cook S, Weilenmann D, Kaiser  
52  
53 C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Juni P,  
54  
55 Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting  
56  
57 stents for primary percutaneous coronary revascularisation of acute myocardial infarction.  
58  
59  
60

- 1  
2  
3  
4 *EUROINTERVENTION*.(2016)12: e1343-e1354. doi:10.4244/EIJY15M12\_09  
5  
6  
7  
8 15.Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent  
9  
10 apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary  
11  
12 percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting  
13  
14 stents implanted for stable/unstable angina: insights from optical coherence tomography. *JACC Cardiovasc*  
15  
16 *Interv.*(2009)2: 445-52. doi:10.1016/j.jcin.2009.01.012  
17  
18  
19  
20  
21 16.Raber L, Baumgartner S, Garcia-Garcia HM, Kalesan B, Justiz J, Pilgrim T, Moschovitis A, Khattab AA,  
22  
23 Buellesfeld L, Wenaweser P, Meier B, Serruys PW, Juni P, Windecker S. Long-term vascular healing in  
24  
25 response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study. *JACC*  
26  
27 *Cardiovasc Interv.*(2012)5: 946-57. doi:10.1016/j.jcin.2012.05.012  
28  
29  
30  
31  
32 17.Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M,  
33  
34 Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular  
35  
36 ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late  
37  
38 drug-eluting stent thrombosis. *CIRCULATION*.(2009)120: 391-9.  
39  
40  
41  
42  
43 18.de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Juni P, Kastrati A, Windecker S.  
44  
45 Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute  
46  
47 ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three  
48  
49 randomised trials. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on*  
50  
51 *Interventional Cardiology of the European Society of Cardiology*.(2015)10: 1425.  
52  
53  
54  
55  
56 19.Kim H, Kang J, Hwang D, Han J, Yang H, Kang H, Koo B, Kim SY, Park K, Rha S, Shin W, Lim H, Park K,  
57  
58 Park KW. Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous  
59  
60



- 1  
2  
3  
4 Coronary Intervention in Patients with Acute Coronary Syndrome. *CIRCULATION*.(2021)143: 1081-1091.  
5  
6 doi:10.1161/CIRCULATIONAHA.120.051700  
7  
8  
9
- 10 20.Lee HJ, Park TK, Song YB, Choi YJ, Yu CW, Yang JH, Hahn J, Choi S, Choi RK, Choi J, Park JS, Kim JS,  
11  
12 Kim TH, Jang HJ, Lee SH, Shim WH, Roh YM, Gwon H. Biodegradable polymer biolimus-eluting stent  
13  
14 versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. *INT J*  
15  
16 *CARDIOL*.(2015)183: 190-197. doi:10.1016/j.ijcard.2015.01.036  
17  
18  
19
- 20 21.Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M,  
22  
23 Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T.  
24  
25 Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients  
26  
27 with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised  
28  
29 superiority trial. *The Lancet*.(2019)394: 1243-1253. doi:10.1016/S0140-6736(19)31877-X  
30  
31  
32  
33
- 34 22.ZHANG QI, QIU JP, KIRTANE AJ, ZHU TQ, ZHANG RY, YANG ZK, HU J, DING FH, DU R, SHEN  
35  
36 WF. Comparison of Biodegradable Polymer Versus Durable Polymer Sirolimus-Eluting Stenting in Patients  
37  
38 with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention:  
39  
40 Results of the RESOLVE Study. *J INTERV CARDIOL*.(2014)27: 131-141. doi:10.1111/joic.12102  
41  
42  
43  
44
- 45 23.Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuillomenet A, Muller O, Cook S, Weilenmann D, Kaiser  
46  
47 C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blöchlinger S, Wenaweser P, Jüni P,  
48  
49 Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting  
50  
51 stents for primary percutaneous coronary revascularisation of acute myocardial infarction.  
52  
53 *EUROINTERVENTION*.(2016)12: e1343-e1354. doi:10.4244/EIJY15M12\_09  
54  
55  
56  
57
- 58 24.Zhang Y, Iqbal J, Windecker S, Linke A, Antoni D, Sohn HY, Corti R, van Es G, Copt S, Eerdmans P, Saitta  
59  
60

- 1  
2  
3  
4 R, Morice M, Di Mario C, Juni P, Wijns W, Buszman P, Serruys PW. Biolimus-eluting stent with  
5  
6 biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction.  
7  
8  
9 *HEART*.(2015)101: 271-278. doi:10.1136/heartjnl-2014-306359  
10  
11  
12 25.Pilgrim T, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Losdat S,  
13  
14 Eeckhout E, Valgimigli M, Juni P, Windecker S, Iglesias JF. Biodegradable- Versus Durable-Polymer  
15  
16 Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial. *JACC Cardiovasc*  
17  
18 *Interv.*(2021)14: 639-648. doi:10.1016/j.jcin.2020.12.011  
19  
20  
21  
22  
23 26.Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N,  
24  
25 Mihalscik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ,  
26  
27 Mehran R, Stone GW. Strut coverage and late malapposition with paclitaxel-eluting stents compared with  
28  
29 bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing  
30  
31 Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial.  
32  
33 *CIRCULATION*.(2011)123: 274-81. doi:10.1161/CIRCULATIONAHA.110.963181  
34  
35  
36  
37  
38  
39 27.Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S, Guo L, Mori H, Harari E, Paek KH,  
40  
41 Fernandez R, Chahal D, Romero ME, Kolodgie FD, Gupta A, Virmani R, Finn AV. Drug-eluting coronary  
42  
43 stents: insights from preclinical and pathology studies. *NAT REV CARDIOL*.(2020)17: 37-51.  
44  
45  
46  
47  
48  
49  
50  
51 28.Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents,  
52  
53 durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery  
54  
55 disease: mixed treatment comparison meta-analysis. *BMJ*.(2013)347: f6625. doi:10.1136/bmj.f6625  
56  
57  
58  
59 29.Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige  
60

- 1  
2  
3  
4 G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary  
5  
6 stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a  
7  
8 large two-institutional cohort study. *LANCET*.(2007)369: 667-78. doi:10.1016/S0140-6736(07)60314-6  
9  
10  
11  
12 30.Siqueira DA, Abizaid AA, Costa JR, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A,  
13  
14 Centemero M, Sousa AG, Sousa JE. Late incomplete apposition after drug-eluting stent implantation:  
15  
16 incidence and potential for adverse clinical outcomes. *EUR HEART J*.(2007)28: 1304-9.  
17  
18 doi:10.1093/eurheartj/ehm114  
19  
20  
21  
22  
23 31.Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S,  
24  
25 Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in  
26  
27 patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the  
28  
29 ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *EUR HEART J*.(2012)33: 1214-22.  
30  
31  
32  
33  
34  
35  
36  
37  
38 32.Guagliumi G, Shimamura K, Sirbu V, Garbo R, Boccuzzi G, Vassileva A, Valsecchi O, Fiocca L, Canova P,  
39  
40 Colombo F, Tensol RPG, Nakamura D, Attizzani GF, Cereda A, Satogami K, De Luca L, Saia F, Capodanno  
41  
42 D. Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or  
43  
44 biodegradable-polymer drug-eluting stents. *EUR HEART J*.(2018)39: 2448-2456.  
45  
46  
47  
48  
49  
50  
51 33.Kuramitsu S, Kazuno Y, Sonoda S, Domei T, Jinnouchi H, Yamaji K, Soga Y, Shirai S, Ando K, Saito S.  
52  
53 Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting  
54  
55 stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. *Eur Heart*  
56  
57 *J Cardiovasc Imaging*.(2016)17: 34-40. doi:10.1093/ehjci/jev203  
58  
59  
60

**Table 1. The characteristics of the included trails**

Authors	Years	Journal	Study	Center	Country	Follow up	NO.patients	
							BP-DES	DP-DES
Hyo-Soo Kim	2021	Circulation	RCT	multicentre	Korea	12 month	1700	1713
Thomas Pilgrim	2021	JACC	RCT	multicentre	Switzerland	24month	649	651
Juan F Iglesias	2019	The Lancet	RCT	multicentre	Switzerland	12 month	649	651
Thomas Pilgrim	2016	EuroIntervention	RCT	multicentre	Switzerland	12 month	211	196
Yao-Jun Zhang	2015	Heart	RCT	multicentre	Netherlands	60month	280	293
Hyun Jong Lee	2015	International journal of cardiology	RCT	multicentre	Korea	24month	171	536
Antoinette de Waha	2015	EuroIntervention	RCT	multicentre	multicentre	48month	291	206
Antoinette de Waha	2015	EuroIntervention	RCT	multicentre	multicentre	12month	291	206
Qi Zhang	2014	Journal of Interventional Cardiology	RCT	multicentre	China	12 month	596	596

**Table 2. The baseline features of the patients**


Authors	basic characters									
	Age		SEX(MALE)		Body mass index		Hypertension		Diabetes	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim	63.1±11.1	63.0±11.1	1337	1351	25.0±3.2	24.9±3.1	1147	1095	747	789
Juan F Iglesias	62.2±11.8	63.2±11.8	513	477	26.9± 4.3	26.8± 4.3	281	297	73	82
Thomas Pilgrim	61.3±12.4	61.7±12.7	170	151	27.0±4.3	27.0±4.3	102	98	30	27
Yao-Jun Zhang	62.9±11.7	62.8±11.7	215	210	27.5±4.4	27.8±4.6	181	198	55	46
Hyun Jong Lee	64±14.08	63±14.08	128	400	/	/	102	308	82	269
Antoinette de Waha	62.5±12.1	63.1±12.6	214	149	/	/	142	110	56	34
Antoinette de Waha	62.5±12.1	63.1±12.6	214	149	/	/	142	110	56	34
Qi Zhang	63.9±13.1	64.1±12.1	475	467	/	/	360	376	129	113

**Table 2. The baseline features of the patients**


Authors	basic characters									
	Dyslipidemia		smoking		LVEF, %		Stent number per person		Total stent length, mm	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim <sup>1</sup>	1,247	1,280	515	475	58.7±10.4	58.5±10.4	1.7±1.1	1.7±1.0	42.9±31.9	41.7±30.2
Juan F Iglesias	304	302	294	250	49.0 ± 11.0	48.4 ± 11.2	1.37 ± 0.64	1.3 ± 0.66	31.91± 18.21	33.92± 19.76
Thomas Pilgrim	110	101	93	77	49.5±10.9	48.3±11.1	1.42±0.71	1.19±0.71	29.49±17.83	30.52±18.99
Yao-Jun Zhang	152	176	107	115	51.5±10.1	51.4±11.8	2.2±0.5	2.2±0.6	26.6±15	27.9±15.2
Hyun Jong Lee	116	389	65	228	55 (45–65)	52 (43–62)	/	/	/	/
Antoinette de Waha <sup>1</sup>	119	109	120	90	47±10	48±12	/	/	25.9±12.6	27.7±14.2
Antoinette de Waha	119	109	120	90	47±10	48±12	/	/	25.9±12.6	27.7±14.2
Qi Zhang	87	76	257	223	50±12	49.0 ± 17.0	/	/	/	/

**Fig1. A Baseline characteristics and stent information of patients with ACS**


1) Age




2) Sex (male)



3) Body mass index




4) Hypertension




209x297mm (300 x 300 DPI)

Fig1. B Baseline characteristics and stent information of patients with ACS


5) Diabetes




6) Dyslipidemia



7) Smoking



8) LVEF




209x297mm (300 x 300 DPI)




Fig 1. C. Baseline characteristics and stent information of patients with ACS

## 9) Stent number per person




## 10) Total stent length




209x297mm (300 x 300 DPI)

**Fig2. Primary endpoint: MACE**


2.1) MACE during follow up period



2.2) MACE at 1 year




2.3) MACE over 2 years




209x297mm (300 x 300 DPI)

**Fig3. Target vessel revascularization (TVR)**


3.1) Target vessel revascularization (TVR) during follow up period



3.2) Target vessel revascularization (TVR) at 1 year




3.3) Target vessel revascularization (TVR) over 2 years




209x297mm (300 x 300 DPI)

**Fig4. Target lesion revascularization(TLR)**


4.1) Target lesion revascularization(TLR) during follow up period



4.2) Target lesion revascularization(TLR) at 1 year




4.3) Target lesion revascularization(TLR) over 2 years




209x297mm (300 x 300 DPI)

**Fig 5. All cause death**


5.1) All cause death during follow up period



5.2) All cause death at 1 year




5.3) All cause death over 2 years




209x297mm (300 x 300 DPI)

**Fig 6. cardiac death**


6.1) cardiac death during follow up period



6.2) cardiac death at 1 year




6.3) cardiac death over 2 years




209x297mm (300 x 300 DPI)

Fig 7. Target vessel myocardial infarction (MI)


## 7.1) Target vessel myocardial infarction (MI) during follow up period



## 7.2) Target vessel myocardial infarction (MI) at 1 year




## 7.3) Target vessel myocardial infarction (MI) over 2 year




209x297mm (300 x 300 DPI)

**Fig 8. Stent thrombosis**


8.1) Stent thrombosis during follow up period



8.2) Stent thrombosis at 1 year



8.3) Stent thrombosis over 2 years



209x297mm (300 x 300 DPI)





## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Title page
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract page
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 7-9
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 9-11
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	



# PRISMA 2020 Checklist

1136/bmjopen-2021-058075 on 8 June 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 11-15
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	
Study characteristics	17	Cite each included study and present its characteristics.	
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 15-17
	23b	Discuss any limitations of the evidence included in the review.	
	23c	Discuss any limitations of the review processes used.	
	23d	Discuss implications of the results for practice, policy, and future research.	
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 8
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	
Competing interests	26	Declare any competing interests of review authors.	
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	



# PRISMA 2020 Checklist

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only

# BMJ Open

## Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058075.R1
Article Type:	Original research
Date Submitted by the Author:	22-Feb-2022
Complete List of Authors:	<p>Yuan, Haoyong; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Wu, Zhongshi; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Lu, Ting; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Wei, Tingting; Hunan Provincial Maternal and Child Health Care Hospital, Department of Paediatrics</p> <p>Zeng, Yifan; Central South University, Department of Cardiovascular Surgery</p> <p>Liu, Yalin; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p> <p>Huang, Can; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials</p>
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Medical management
Keywords:	Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Myocardial infarction < CARDIOLOGY
<p>Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.</p> <p>726399_Figure_1.tif  726399_Figure_2.tif  726399_Figure_3.tif  726399_Figure_4.tif  726399_Figure_5.tif  726399_Figure_6.tif  726399_Figure_7.tif  726399_Figure_8.tif</p>	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

726399\_Figure\_9.tif  
726399\_Figure\_10.tif

SCHOLARONE™  
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2021-058075 on 8 June 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary**  
5  
6 **syndrome: a meta-analysis**  
7  
8

9 Haoyong Yuan, MD<sup>1,2</sup>, Zhongshi Wu, MD<sup>1,2</sup>, Ting Lu, MD<sup>1,2</sup>, Tingting Wei, MD<sup>3</sup>, Yifan Zeng,  
10  
11 MD<sup>1</sup>, Yalin Liu<sup>1,2</sup>, Can Huang, MD<sup>1,2\*</sup>  
12  
13

14  
15 <sup>1</sup>Department of Cardiovascular Surgery, the Second Xiangya Hospital of Central South  
16  
17 University, Changsha, Hunan 410011, China  
18  
19

20  
21 <sup>2</sup>Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials, Changsha,  
22  
23 Hunan 410008, China  
24  
25

26  
27 <sup>3</sup>Department of Paediatrics, Hunan Provincial Maternal and Child Health Care Hospital,  
28  
29 Changsha, Hunan 410008, China  
30  
31

32  
33  
34  
35  
36 **\*Corresponding author:** Can Huang  
37

38  
39 Department of Cardiovascular Surgery, Second Xiangya Hospital, Central South University,  
40  
41 #139 Renmin Road, Changsha, Hunan, 410011, P.R. China  
42  
43

44 Tel: +86 73185292133  
45

46 Fax: +86 73185292133  
47

48  
49 E-mail: huangcan413@csu.edu.cn  
50  
51

52  
53 Word count: 2939  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** To compare the safety and effectiveness between biodegradable polymer drug-eluting stents (BP-DES) and durable polymer drug-eluting stents (DP-DES) in patients with acute coronary syndrome (ACS).

**Design:** Meta-analysis of randomized controlled trials (RCTs)

**Primary and secondary outcome measures:** Major adverse cardiovascular events (MACEs) were considered the primary endpoint. Efficacy endpoints included target vessel revascularization (TVR) and target lesion revascularization (TLR). Safety endpoints included all-cause death, cardiac death, target vessel myocardial infarction (TVMI), and ST.

**Methods:** We searched PubMed, Medline, Embase, and the Cochrane Controlled Register of Trials (CENTRAL) for comparative studies of BP-DES and DP-DES in patients with ACS from January 2000 to July 2021. Statistical pooling was performed for estimating incidence, using a random-effects model with generic inverse-variance weighting. Risk estimates were computed with 95% confidence intervals (CIs).

**Results:** Eight articles with 7 trails that compared BP-DES and DP-DES in patients with ACS were identified and included in qualitative and quantitative analyses. There was no difference in the baseline characteristics ( $p>0.05$ ), except for the number of smoking patients ( $p=0.008$ ), which was significantly lower in the BP-DES group. The meta-analysis demonstrated that MACEs, efficacy endpoints, and safety endpoints were similar between the groups at 1 year ( $p>0.05$ ). However, the total stent thrombosis (ST) incidence was significantly different between the BP-DES and DP-DES groups in the follow-up period ( $p=0.0001$ ). Further



1  
2  
3  
4 analysis showed a statistically significant difference in MACEs ( $p=0.002$ ), TLR ( $p=0.05$ ), TVR  
5  
6 ( $p=0.002$ ), total ST incidence ( $p=0.0001$ ), and ST incidence ( $p=0.002$ ) over 2 years.  
7  
8

9  
10 **Conclusion:** This meta-analysis revealed that both stent types showed excellent safety and  
11  
12 efficacy profiles at 12 months. However, a slight increase in MACEs, TLR, TVR, and ST  
13  
14 incidence was observed in the DP-DES group over the 2-year follow-up period, suggesting that  
15  
16 BP-DES may be more favorable when treating patients with ACS. Long-term follow-ups are  
17  
18 necessary to confirm these findings.  
19  
20  
21  
22

23 **Keywords:** acute coronary syndrome, biodegradable drug-eluting stent, durable polymer drug-  
24  
25 eluting stent, major adverse cardiac event, stent thrombosis, target lesion revascularization,  
26  
27 target vessel revascularization  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- This meta-analysis includes randomized controlled trials with long-term follow-ups.
- The large sample size ensures adequate statistical power to detect even a small effect of interest.
- Heterogeneity among the BP-DES may distort the reported results.
- The differences in the durations of dual antiplatelet therapy may influence clinical outcomes.

For peer review only

### **Data availability statement**

No additional data available.

### **Patient and public involvement**

We did not require patient and public involvement, as this is a meta-analysis, and no new patients were enrolled in the study.

### **Ethics approval**

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the protocol was registered with PROSPERO (CRD42021253412). This study was approved by the institutional review board of the Second Xiangya Hospital of Central South University.

### **Funding**

This work was supported by the Hunan Provincial Natural Science Foundation of China (grant number 2020JJ4787).

## INTRODUCTION

Percutaneous coronary intervention (PCI) is the current standard of care for patients with coronary artery disease, particularly acute coronary syndrome (ACS)<sup>[1, 2]</sup>. Unlike bare-metal stents (BMS), drug-eluting stents (DES) use antiproliferative agents embedded in a polymer coating on the stent's surface, which inhibit neointimal hyperplasia to reduce the risk of restenosis<sup>[3]</sup>. Although DES have substantially improved clinical outcomes, the first-generation durable polymer DES (DP-DES) released sirolimus or paclitaxel, and it was associated with similar risks of death and myocardial infarction to those of BMS beyond 1 year after implantation<sup>[4]</sup>. Later, the second-generation DP-DES were confirmed to have lower restenosis rates than first-generation devices and showed reduced rates of stent thrombosis (ST)<sup>[5]</sup>. Recently, very late ST and neoatherosclerosis, with adverse clinical outcomes, have been observed with second-generation DP-DES, which has improved the biocompatibility of the polymer<sup>[6]</sup>. Late stent failure has been attributed to delayed endothelial healing secondary to a hypersensitivity reaction to the durable polymer<sup>[7]</sup>.

To address this potential limitation of DP-DES, biodegradable polymer DES (BP-DES) have been developed. Theoretically, BP-DES would lead to a reduction in vascular inflammation and a decreased risk of late stent-related complications due to the advantage of leaving only the BMS after complete drug elution and polymer degradation. BP-DES have been observed to reduce the rate of major adverse cardiac events (MACEs) compared to BMS<sup>[8]</sup> and first-generation DP-DES<sup>[9]</sup>. Studies of patients who underwent PCI showed that the device-related outcomes were comparable between BP-DES and second-generation DP-DES<sup>[10-13]</sup>. Thus, BP-DES would be expected to reduce the risk of ST-related MACEs beyond the first

1  
2  
3  
4 year compared to that of DP-DES. However, previous studies enrolled a significant proportion  
5  
6 of stable angina patients. ACS confers an increased risk of adverse outcomes due to plaque  
7  
8 characteristics, including culprit lesions, thrombus burden, and persistent inflammation,  
9  
10 compared to stable coronary artery diseases. ACS also increases the risk of delayed arterial  
11  
12 healing and vessel remodeling<sup>[14]</sup>, reflected by higher rates of incomplete stent strut coverage<sup>[15,</sup>  
13  
14  
15  
16  
17 <sup>16]</sup> and malpositioning<sup>[17]</sup>.

18  
19  
20 Recently, randomized trials have been performed to compare the efficacy and safety of  
21  
22 DP-DES and BP-DES in patients with ACS who underwent PCI. In this meta-analysis, we  
23  
24 aimed to summarize studies comparing the two polymer technologies in ACS patients and to  
25  
26 analyze the safety and effectiveness of these therapeutic options.  
27  
28  
29

## 30 31 **METHODS**

### 32 33 34 *Search strategy and registration*

35  
36  
37 This study was conducted according to the Preferred Reporting Items for Systematic  
38  
39 Reviews and Meta-Analyses (PRISMA) guidelines and was approved by the institutional  
40  
41 review board of the Second Xiangya Hospital, Central South University. The protocol was  
42  
43 registered with PROSPERO (CRD42021253412).  
44  
45  
46  
47

48  
49 Based on the PRISMA statement, PubMed, Medline, Embase, and the Cochrane  
50  
51 Controlled Register of Trials (CENTRAL) databases were searched for comparative studies of  
52  
53 BP-DES and DP-DES in the treatment of patients with ACS who underwent PCI. The  
54  
55 following search terms were used: “BP-DES,” “biodegradable,” “bioabsorbable,”  
56  
57 “bioabsorbable polymer drug-eluting stent,” “biodegradable polymer drug-eluting stent,” “DP-  
58  
59  
60

1  
2  
3  
4 DES,” “durable polymer,” “durable polymer drug-eluting stent,” “acute coronary syndrome,”  
5  
6 “ACS,” “AMI,” “Acute myocardial infarction,” “Non ST segment elevation myocardial  
7  
8 infarction,” “ST segment elevation myocardial infarction,” “NSTEMI,” and “STEMI.” We also  
9  
10 reviewed prior meta-analyses and the reference lists of the original trials and review articles to  
11  
12 identify further studies. Only English language articles published in peer-reviewed journals  
13  
14 from January 2000 to July 2021 were selected. Analyses were conducted by two independent  
15  
16 reviewers.  
17  
18  
19  
20  
21

### 22 23 ***Eligibility criteria***

24  
25  
26 The inclusion criteria for this meta-analysis were as follows: 1) randomized controlled  
27  
28 trials (RCTs) comparing BP-DES and DP-DES in the treatment of patients with ACS who  
29  
30 underwent PCI; 2) data reporting patients’ baseline characteristics, follow-up durations,  
31  
32 outcomes at the primary, safety, and efficacy endpoints; 3) mean follow-up time over 12  
33  
34 months; and 4) full-text articles.  
35  
36  
37  
38  
39

40 The exclusion criteria for the meta-analysis were as follows: 1) duplications of samples  
41  
42 and reports (evaluated by 2 independent reviewers); 2) case reports/series; and 3) studies  
43  
44 involving data from a national database.  
45  
46  
47

### 48 49 ***Data extraction and outcome measurement***

50  
51 Two authors (Haoyong Yuan and Tingting Wei) systematically screened the titles and  
52  
53 abstracts of publications retrieved using the search strategy to select studies that met the above  
54  
55 inclusion criteria. Any disagreement between them regarding the eligibility of particular studies  
56  
57 was resolved through discussion and involvement of a third author (Zhongshi Wu), when  
58  
59  
60

1  
2  
3  
4 necessary. First, baseline characteristics, including the name of the first author, year of  
5  
6 publication, study design, country of origin, number of patients, mean age of subjects, and  
7  
8 mean duration of follow-up were gathered from each included article. In addition, sex; body  
9  
10 mass index; presence of hypertension, diabetes, dyslipidemia, chronic kidney disease,  
11  
12 peripheral vessel disease, or smoking; left ventricular ejection fraction (LVEF), number of  
13  
14 stents per person; and total stent length were collected for evaluation of procedure risk. MACEs  
15  
16 were considered the primary endpoint. The efficacy endpoints included target vessel  
17  
18 revascularization (TVR) and target lesion revascularization (TLR). In addition, all-cause death,  
19  
20 cardiac death, target vessel myocardial infarction (TVMI), and ST were employed as endpoints  
21  
22 to evaluate the safety of BP-DESs and DP-DESs.  
23  
24  
25  
26  
27  
28  
29

30 The Risk of Bias 2 (RoB2) tool was employed to assess the quality of RCTs based on  
31  
32 sequence generation; randomized group allocation; concealment; blinding of participants,  
33  
34 personnel, and outcome assessors; incomplete data; selectivity; outcome reporting; and other  
35  
36 sources of bias( Supplementary Material 2)<sup>[18]</sup>.  
37  
38  
39  
40

### 41 ***Data analysis and synthesis***

42  
43  
44  
45 Continuous variables are reported as the mean (standard deviation), and categorical  
46  
47 variables are expressed as numbers. Statistical pooling was performed to estimate incidence,  
48  
49 according to a random-effects model with generic inverse-variance weighting. We computed  
50  
51 risk estimates with 95% confidence intervals (CIs), using RevMan 5.3 (The Cochrane  
52  
53 Collaboration, The NordicCochrane Centre, Copenhagen, Denmark). Hypothesis testing for  
54  
55 superiority was set at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity  
56  
57  
58  
59  
60

1  
2  
3  
4 was set at the two-tailed 0.10 level and was based on the Cochran Q test, with  $I^2$  values of 25%,  
5  
6 50%, and 75% representing mild, moderate, and severe heterogeneity, respectively.  
7  
8

## 9 10 **RESULTS**

### 11 12 13 *Search results*

14  
15  
16 A total of 895 articles, written in English, were identified through the literature search.  
17  
18 After an initial screening of the titles and abstracts, 803 articles were eliminated, as they were  
19  
20 not related to the topic of this study. Following the removal of these articles, 92 clinical studies  
21  
22 and RCT articles of the two polymers remained. After reading the full texts, 28 articles about  
23  
24 acute coronary syndromes remained, with 20 articles including chronic and acute coronary  
25  
26 syndrome. Finally, 8 articles, with 7 randomized controlled trials, comparing BP-DES and DP-  
27  
28 DES in patients with ACS were identified and included in the qualitative and quantitative  
29  
30 analyses<sup>[19-26]</sup>. The follow-up duration ranged from 1 year to 5 years (Supplementary Table 1  
31  
32 and Supplementary Material 1).  
33  
34  
35  
36  
37  
38  
39

### 40 41 *General features of the trials*

42  
43 A total number of 8089 patients (3898 patients who were treated with BP-DES and  
44  
45 4191 patients who were treated with the DP-DES) were included in this analysis. Further  
46  
47 details about the the quality of RCTs, total number of patients retrieved from each trial,  
48  
49 publication years, countries of origin of the publications, centers in which trials were  
50  
51 performed, follow-up durations, risk factors, and primary, efficacy, and safety endpoints  
52  
53 are listed in Supplementary Table 2 and Supplementary Material 2.  
54  
55  
56  
57  
58  
59

### 60 *Patient characteristics*



1  
2  
3  
4 The baseline features of the patients are summarized in Tables 2. The mean age of the  
5  
6 patients who were treated by BP-DES ranged from 61.3 to 64 years old, whereas the mean age  
7  
8 of the patients who were treated by DP-DES ranged from 61.7 to 64.1 years. The proportions  
9  
10 of male patients were above 70% in all included trials. There was no difference in age (mean  
11  
12 difference [MD]: 0.14, 95%CI: -0.66–0.38; p=0.60,  $I^2=0\%$ ), sex (male) (odds ratio [OR]: 1.10,  
13  
14 95%CI: 0.99–1.23; p=0.07,  $I^2=0\%$ ), hypertension (OR: 1.03, 95%CI: 0.94–1.13; p=0.57,  
15  
16  $I^2=37\%$ ), dyslipidemia (OR: 0.92, 95% CI: 0.83–1.02; p=0.10,  $I^2=36\%$ ), LVEF (MD: 0.00,  
17  
18 95%CI: 0.00–0.01; p=0.12,  $I^2=12\%$ ), body mass index (MD:0.07, 95%CI: -0.11 to 0.25; p=0.44,  
19  
20  $I^2=0\%$ ), diabetes (OR: 0.92, 95%CI: 0.83–1.02; p=0.13,  $I^2=21\%$ ), total stent length (MD: -0.72,  
21  
22 95%CI: -2.30 to -0.85; p=0.37,  $I^2=40\%$ ), and number of stents per person (MD: -0.00, 95%CI:  
23  
24 -0.05 to 0.04; p=0.84,  $I^2=0\%$ ) among patients who were implanted with BP-DES or DP-DES.  
25  
26 The meta-analysis demonstrated that the number of smoking patients (OR: 1.13, 95%CI: 1.03–  
27  
28 1.24; p=0.008,  $I^2=29\%$ ) was significantly lower in the BP-DES group than that in the DP-DES  
29  
30 group (Figure 1-3).

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 ***Primary endpoint: MACEs reported during follow-up periods of 1–5 years, 1 year, and over***  
42  
43  
44 ***2 years***

45  
46  
47 MACEs, including all-cause death, recurrent MI, or any coronary repeat revascularization  
48  
49 involving TLR, TVR, and non-TVR, were considered the primary endpoint of the trials. A  
50  
51 meta-analysis indicated no statistically significant difference in MACEs in a follow-up period  
52  
53 ranging from 1 to 5 years between the two groups (OR: 0.87, 95%CI: 0.75–1.01; p=0.07,  
54  
55  $I^2=50\%$ ). Of the 5 studies that published 1-year outcomes, MACEs were not significantly  
56  
57 different between the BP-DES and DP-DES groups (OR: 0.97, 95%CI: 0.81–1.16; p=0.74,  
58  
59  
60

1  
2  
3  
4  $I^2=44\%$ ). However, the MACEs with follow-up periods over 2-years are significant lower in  
5  
6 the BP-DES group (OR: 0.71, 95%CI: 0.57–0.88;  $p=0.002$ ,  $I^2=0\%$ ) (Figure 4).  
7  
8  
9

10  
11  
12  
13 ***Efficacy endpoint: TVR and TLR reported during follow-up periods of 1–5 years, 1 year,***  
14  
15 ***and over 2 years***  
16

17  
18  
19 TLR and TVR were considered the efficacy endpoints of the trials. The meta-analysis  
20  
21 indicated no statistically significant difference in TLR in follow-up periods ranging from 1 to  
22  
23 5 years between the two groups (OR: 0.78, 95%CI: 0.61–1.00;  $p=0.05$ ,  $I^2=48\%$ ). Among the 5  
24  
25 studies that published 1-year data, TLR was not significantly different between the BP-DES  
26  
27 and DP-DES groups (OR: 0.72, 95%CI: 0.40–1.31;  $p=0.29$ ,  $I^2=65\%$ ). The meta-analysis  
28  
29 indicated no statistically significant difference in TVR in follow-up periods ranging from 1 to  
30  
31 5 years (OR: 1.01, 95%CI: 0.79–1.28;  $p=0.96$ ,  $I^2=46\%$ ) or in the 3 publications with 1 year  
32  
33 follow-up periods (OR: 0.98, 95%CI: 0.40–2.38;  $p=0.96$ ,  $I^2=76\%$ ). However, the difference in  
34  
35 TLR was statistically significant in 4 RCT studies with follow-up periods over 2-years (OR:  
36  
37 0.71, 95%CI: 0.51–1.01;  $p=0.05$ ,  $I^2=0\%$ ), and the difference in TVR was also statistically  
38  
39 significant in 3 RCT studies with follow-up periods over 2-years (OR: 0.70, 95%CI: 0.52–0.94;  
40  
41  $p=0.002$ ,  $I^2=15\%$ ), with values much lower in the BP-DES group (Figures 5, 6).  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 ***Safety endpoint: All-cause death, cardiac-related death, target vessel myocardial infarction,***  
52  
53 ***and stent thrombosis over follow-up periods of 1–5 years, 1 year, and over 2 years***  
54

55  
56 All-cause death, cardiac-related death, TVMI, and ST were considered the efficacy  
57  
58 endpoints. The meta-analysis indicated no statistically significant difference between the two  
59  
60

1  
2  
3  
4 groups in all-cause death (OR: 0.88, 95%CI: 0.72–1.07;  $p=0.20$ ,  $I^2=0\%$ ), cardiac-related death  
5  
6 (OR: 0.89, 95%CI: 0.71–1.12;  $p=0.32$ ,  $I^2=20\%$ ), and TVMI (OR: 0.73, 95%CI: 0.53–1.01;  
7  
8  $p=0.05$ ,  $I^2=0\%$ ) over a follow-up period ranging from 1 to 5 years. Of the 5 studies that  
9  
10 published 1-year data, all-cause death, cardiac-related death, and TVMI were also not  
11  
12 significantly different between the BP-DES and DP-DES groups ([all-cause death, OR: 0.91,  
13  
14 95%CI: 0.71–1.15;  $p=0.42$ ,  $I^2=0\%$ ], [cardiac-related death, OR: 0.96, 95%CI: 0.74–1.26;  
15  
16  $p=0.79$ ,  $I^2=35\%$ ], [TVMI, OR: 0.73, 95%CI: 0.53–1.01;  $p=0.05$ ,  $I^2=0\%$ ]). In the 5 studies with  
17  
18 follow up periods of over 2-year, similar findings were observed for the all-cause cardiac death,  
19  
20 cardiac-related death, and TVMI ([all-cause death, OR: 0.85, 95%CI: 0.64–1.12;  $p=0.25$ ,  
21  
22  $I^2=0\%$ ], [cardiac-related death, OR: 0.77, 95%CI: 0.56–1.17;  $p=0.12$ ,  $I^2=0\%$ ], [TVMI, OR:  
23  
24 0.79, 95%CI: 0.51–1.22;  $p=0.28$ ,  $I^2=0\%$ ) (Figures 7–9). However, the total ST incidence,  
25  
26 including the definite ST, probable ST, and definite or probable ST incidence, was significantly  
27  
28 different between the BP-DES and DP-DES groups during the follow-up period (OR:  
29  
30 0.59, 95% CI: 0.46–0.77;  $p=0.0001$ ,  $I^2=48\%$ ). Further analysis revealed no difference in  
31  
32 total ST for a 1-year follow-up (OR: 0.61, 95%CI: 0.32–1.15;  $P=0.13$ ,  $I^2=72\%$ ), while the  
33  
34 meta-analysis indicated a statistically significant difference in the total ST for the follow-ups  
35  
36 over 2-years (OR: 0.63, 95%CI: 0.47–0.85;  $p=0.002$ ,  $I^2=0\%$ ) (Figure 10).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 DISCUSSION

49  
50  
51  
52 The choice of stent in patients undergoing PCI for ACS is debated. Coronary intervention  
53  
54 with second-generation DP-DES generally reduces the need for revascularization and improves  
55  
56 mortality compared to BMS and first-generation DP-DES. Furthermore, the risk of late ST with  
57  
58 DP-DES tends to off-set these benefits, as seen in registries and clinical trials comparing DP-  
59  
60

DES to BMS<sup>[15, 27]</sup>. BP-DES was designed to leave only the BMS behind once the polymer completely bio-degraded after drug elution and may represent an attractive solution for patients with ACS<sup>[28]</sup>. Prior meta-analyses have compared the clinical outcomes among BMS, DP-DES, and BP-DES in patients with stable coronary artery disease, but no previous meta-analysis of RCTs and prospective trials directly compared clinical outcomes between BP-DES and DP-DES for the treatment of ACS. To our knowledge, this meta-analysis exclusively compared BP-DES to DP-DES. It included 7 trials representing 8089 patients with relatively long follow-up durations, ranging from 1 year to 5 years. Although BP-DES have been hypothesized to offer improved outcomes, mainly in the long term, several prior meta-analyses have demonstrated different outcomes with BP-DES compared to DP-DES in patients undergoing PCI. Bangalore et al. found that BP-DES were associated with higher mortality than DP-DES beyond 1 year of follow-up<sup>[29]</sup>. El-Hayek et al. demonstrated no significant difference in mortality between these types of stent<sup>[6]</sup>. In our study, there were no significant differences in MACEs, all-cause death, cardiac-related death, TVMI, TVR, or TLR at a follow-up period of 1 year and no significant differences in all-cause death, cardiac death, or TVMI at a follow-up period of over 2 years. However, at a follow-up of over 2-years, MACEs, TVR and TLR are significant lower in the BP group than those in the DP group. Pilgrim T et al. found a higher all-cause mortality among patients treated with BP-SES compared with DP-EES in the BIOSCIENCE trial; they also found comparable rates of all-cause mortality between patients treated with BP-SES and DP-EES in the BIOSTEMI trial with a 2-year follow-up<sup>[6]</sup>. Mario Iannaccone et al. found that BP-DES might potentially decrease the risk of ischemic events in selected high-risk subgroups of patients, although the two DES stents share the same safety

1  
2  
3  
4 factors for patients in high-anatomical-risk settings like left main (LM) disease<sup>[30]</sup>. Together,  
5  
6 these findings suggest that BP-DES share similar outcomes in terms of MACEs (all-cause death,  
7  
8 cardiac-related death, TVMI, TVR, and TLR) during a 1-year follow-up and might  
9  
10 significantly improve clinical outcomes over a 2-year follow-up.  
11  
12  
13  
14

15 ST is defined as a thrombotic occlusion of a coronary stent<sup>[31]</sup> and is a major complication.  
16  
17 The risk of ST, particularly late ST (occurring beyond 30 days), remains among the major  
18  
19 concerns limiting the use of DES in the treatment of ACS<sup>[32]</sup>. Early-generation DP-DES were  
20  
21 associated with increased rates of very late (>1 year) ST compared with BMS. It was  
22  
23 hypothesized that the mechanism underlying late ST with first DP-DES in ACS was related to  
24  
25 adverse reactions with the durable polymer<sup>[33]</sup>, and the use of more biocompatible polymers  
26  
27 has been associated with a reduction in ST in high-risk patients<sup>[9]</sup>. In the LEADERS trial, the  
28  
29 rate of very late ST was lower with the use of the BP-DES than that with DP-DES<sup>[34]</sup>. Our data  
30  
31 demonstrated that both BP-DES and DP-DES have similar risks of ST beyond 1 year. However,  
32  
33 BP-DES are associated with a significantly reduced risk of ST at a follow-up of over 2 years  
34  
35 compared with DP-DES (OR: 0.64, 95%CI: 0.46–0.88;  $p=0.006$ ,  $I^2=0\%$ ). In contrast, Kim et  
36  
37 al. found that the incidence of ST by groups showed numerically lower rates in the DP-DES  
38  
39 group (0.1%) than those in the BP-DES group and that all late ST cases occurred in those  
40  
41 receiving thick-strut BP-DES stents. They proposed that no meaningful differences in terms of  
42  
43 ST could be identified between the different polymer technologies by intravascular imaging  
44  
45 and that the association of polymer technology and the risk of the ST was difficult to prove<sup>[20,</sup>  
46  
47 <sup>35, 36]</sup>. Therefore, it may be hypothesized that the BP-DES result in improved arterial healing,  
48  
49 which not only minimizes the risk of ST, but also improves the long-term durability of the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 antirestenotic efficacy in the long term, although the two groups have a similar risk of ST  
5  
6 beyond 1 year.  
7  
8

### 9 10 **Limitations**

11  
12  
13 The present study had several limitations. First, this study included RCTs and shares the  
14  
15 limitations of original studies. Second, BP-DES are a heterogeneous group of stents, differing  
16  
17 with regards to stent platform thickness, time to complete degradation of the polymer, and  
18  
19 drug-elution kinetics. DP-DES is an equally heterogeneous group. Innaccone et al. found that  
20  
21 lower strut thickness would have a positive clinical outcome, reducing stent thrombosis and  
22  
23 target lesion revascularizations<sup>[37]</sup>. We were unable to match the stents in regard to strut  
24  
25 thickness. As a consequence, the reported results may not be generalizable to all stents from  
26  
27 the respective group. Third, over-6-month dual antiplatelet therapy (DAPT) was given to the  
28  
29 patients in our including RCT trials. D'Ascenzo et al. found a similar rate of MACEs between  
30  
31 durable and biodegradable polymers, irrespective of DAPT length, and the DAPT duration  
32  
33 seems to partially impact the risk of adverse events of different types of stents at follow-up<sup>[38]</sup>.  
34  
35 Thus, we remain concerned that the duration differences of DAPT may influence the clinical  
36  
37 outcomes.  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **CONCLUSION**

48  
49  
50  
51 In this meta-analysis comparing BP-DES to DP-DES in ACS patients who underwent PCI,  
52  
53 the data indicated that both polymer types showed excellent safety and efficacy profiles at 1  
54  
55 year. There was a slightly increased incidence of MACEs, TLR, TVR, and ST in the DP-DES  
56  
57 group in the follow-up period over 2 years, suggesting that BP-DES may be more favorable for  
58  
59  
60

1  
2  
3  
4 treating patients with ACS. These findings should be confirmed by long-term follow-up in  
5  
6 RCT trials.  
7  
8  
9  
10

### 11 **Author contributions**

12  
13  
14  
15 Can Huang, Zhongshi Wu, and Haoyong Yuan developed the idea of the study, participated in  
16  
17 its design and coordination and helped to draft the manuscript. Ting Lu and Tingting Wei  
18  
19 contributed to the acquisition and interpretation of data. Yifan Zeng and Yalin Liu provided  
20  
21 critical review and substantially revised the manuscript. All authors read and approved the final  
22  
23 manuscript.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**SUPPLEMENTARY TABLE LEGENDS**

Table 1. The characteristics of the included trials

Table 2. The baseline features of the patients

**FIGURE LEGENDS**

Figure 1 . Baseline characteristics and stent information of patients with acute coronary syndrome

Figure 2. Baseline characteristics and stent information of patients with acute coronary syndrome

Figure 3. Baseline characteristics and stent information of patients with acute coronary syndrome

Figure 4. Primary endpoint: major adverse cardiac events

Figure 5. Target vessel revascularization

Figure 6. Target lesion revascularization

Figure 7. All-cause death

Figure 8. Cardiac-related death

Figure 9. Target vessel myocardial infarction

Figure 10. Stent thrombosis



## 参考文献

- [1] Mehta S R, Cannon C P, Fox K A, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials[J]. *JAMA*, 2005,293(23):2908-2917.
- [2] Fox K A, Clayton T C, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data[J]. *J Am Coll Cardiol*, 2010,55(22):2435-2445.
- [3] Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from preclinical and pathology studies[J]. *Nat Rev Cardiol*, 2020,17(1):37-51.
- [4] Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial[J]. *JAMA*, 2008,299(15):1788-1799.
- [5] Raber L, Magro M, Stefanini G G, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study[J]. *Circulation*, 2012,125(9):1110-1121.
- [6] El-Hayek G, Bangalore S, Casso D A, et al. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents[J]. *JACC Cardiovasc Interv*, 2017,10(5):462-473.
- [7] Finn A V, Nakazawa G, Kolodgie F D, et al. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?[J]. *JACC Cardiovasc Interv*, 2009,2(4):300-302.
- [8] Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial[J]. *JAMA*, 2012,308(8):777-787.
- [9] Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial[J]. *Lancet*, 2012,380(9852):1482-1490.
- [10] von Birgelen C, Kok M M, van der Heijden L C, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial[J]. *Lancet*, 2016,388(10060):2607-2617.
- [11] Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial[J].

- Lancet, 2014,384(9960):2111-2122.
- [12] Smits P C, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial[J]. Lancet, 2013,381(9867):651-660.
- [13] Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial[J]. J Am Coll Cardiol, 2013,62(3):181-190.
- [14] Pilgrim T, Piccolo R, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction[J]. EuroIntervention, 2016,12(11):e1343-e1354.
- [15] Gonzalo N, Barlis P, Serruys P W, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography[J]. JACC Cardiovasc Interv, 2009,2(5):445-452.
- [16] Raber L, Baumgartner S, Garcia-Garcia H M, et al. Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study[J]. JACC Cardiovasc Interv, 2012,5(9):946-957.
- [17] Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis[J]. Circulation, 2009,120(5):391-399.
- [18] Sterne J A, Hernan M A, Reeves B C, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions[J]. BMJ, 2016,355:i4919.
- [19] de Waha A, King L A, Stefanini G G, et al. Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials[J]. EuroIntervention, 2015,10(12):1425-1431.
- [20] Kim H S, Kang J, Hwang D, et al. Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial[J]. Circulation, 2021,143(11):1081-1091.
- [21] Lee H J, Park T K, Song Y B, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction[J]. Int J Cardiol, 2015,183:190-197.
- [22] Iglesias J F, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus

- 1  
2  
3 durable polymer everolimus-eluting stents in patients with ST-segment elevation  
4 myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority  
5 trial[J]. *Lancet*, 2019,394(10205):1243-1253.  
6  
7
- 8 [23] Zhang Q, Qiu J P, Kirtane A J, et al. Comparison of biodegradable polymer versus durable  
9 polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction  
10 undergoing primary percutaneous coronary intervention: results of the RESOLVE study[J].  
11 *J Interv Cardiol*, 2014,27(2):131-141.  
12  
13
- 14 [24] Pilgrim T, Piccolo R, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus  
15 durable polymer everolimus-eluting stents for primary percutaneous coronary  
16 revascularisation of acute myocardial infarction[J]. *EuroIntervention*,  
17 2016,12(11):e1343-e1354.  
18  
19
- 20 [25] Zhang Y J, Iqbal J, Windecker S, et al. Biolimus-eluting stent with biodegradable polymer  
21 improves clinical outcomes in patients with acute myocardial infarction[J]. *Heart*,  
22 2015,101(4):271-278.  
23  
24
- 25 [26] Pilgrim T, Muller O, Heg D, et al. Biodegradable- Versus Durable-Polymer Drug-Eluting  
26 Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial[J]. *JACC Cardiovasc*  
27 *Interv*, 2021,14(6):639-648.  
28  
29
- 30 [27] Guagliumi G, Costa M A, Sirbu V, et al. Strut coverage and late malapposition with  
31 paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction:  
32 optical coherence tomography substudy of the Harmonizing Outcomes with  
33 Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial[J].  
34 *Circulation*, 2011,123(3):274-281.  
35  
36  
37
- 38 [28] Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from  
39 preclinical and pathology studies[J]. *Nat Rev Cardiol*, 2020,17(1):37-51.  
40  
41
- 42 [29] Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting  
43 stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed  
44 treatment comparison meta-analysis[J]. *BMJ*, 2013,347:f6625.  
45  
46
- 47 [30] Iannaccone M, Barbero U, De Benedictis M, et al. Comparison of bioresorbable vs durable  
48 polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP  
49 VII Study)[J]. *BMC Cardiovasc Disord*, 2020,20(1):225.  
50  
51
- 52 [31] Modi K, Soos M P, Mahajan K. Stent Thrombosis[J]. 2022.  
53
- 54 [32] Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of  
55 sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large  
56 two-institutional cohort study[J]. *Lancet*, 2007,369(9562):667-678.  
57  
58
- 59 [33] Siqueira D A, Abizaid A A, Costa J R, et al. Late incomplete apposition after drug-eluting  
60 stent implantation: incidence and potential for adverse clinical outcomes[J]. *Eur Heart J*,

2007,28(11):1304-1309.

- [34] Stefanini G G, Byrne R A, Serruys P W, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials[J]. *Eur Heart J*, 2012,33(10):1214-1222.
- [35] Guagliumi G, Shimamura K, Sirbu V, et al. Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents[J]. *Eur Heart J*, 2018,39(26):2448-2456.
- [36] Kuramitsu S, Kazuno Y, Sonoda S, et al. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial[J]. *Eur Heart J Cardiovasc Imaging*, 2016,17(1):34-40.
- [37] Iannaccone M, Gatti P, Barbero U, et al. Impact of strut thickness and number of crown and connectors on clinical outcomes on patients treated with second-generation drug eluting stent[J]. *Catheter Cardiovasc Interv*, 2020,96(7):1417-1422.
- [38] D'Ascenzo F, Iannaccone M, Saint-Hilary G, et al. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients[J]. *Eur Heart J*, 2017,38(42):3160-3172.

### 校对报告

当前使用的样式是 [中华人民共和国国家标准\_GBT\_7714-2005]

当前文档包含的题录共 43 条

有 0 条题录存在必填字段内容缺失的问题

所有题录的数据正常

## Supplementary Material 1: search strategie and PRISMA flow chart for included studies

### A. Search strategie

#### 1. Pubmed (N=688)

**Search date:** from January 2000 to July 2021

**Search terms:**

1#. ("BP-DES"[MeSH Terms] OR "BP-DES"[All Fields] OR "biodegradable "[All Fields] OR "bioabsorbable "[All Fields] OR "bioabsorbable polymer drug-eluting stent"[All Fields] OR "biodegradable polymer drug-eluting stent"[All Fields]) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

2#. ("DP-DES"[All Fields] OR "DP-DES"[MeSH Terms] OR "durable polymer"[All Fields] OR "durable polymer drug-eluting stent"[All Fields] ) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

3#. ("BP-DES"[MeSH Terms] OR "BP-DES"[All Fields] OR "biodegradable "[All Fields] OR "bioabsorbable "[All Fields] OR "bioabsorbable polymer drug-eluting stent"[All Fields] OR "biodegradable polymer drug-eluting stent"[All Fields]) and ("DP-DES"[All Fields] OR "DP-DES"[MeSH Terms] OR "durable polymer"[All Fields] OR "durable polymer drug-eluting stent"[All Fields] ) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

#### 2. OVID (N=207, EMBS=134, MEDLINE=54, Controlled Register of Trials=19)

**Search date:** from January 2000 to July 2021


**Search terms:**

1#.( "BP-DES" OR "bioabsorbable polymer drug-eluting stent" OR "biodegradable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

2#.( "DP-DES" OR "durable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

3#.( "BP-DES" OR "bioabsorbable polymer drug-eluting stent" OR "biodegradable polymer drug-eluting stent" ) and ( "DP-DES" OR "durable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

#### B. PRISMA flow chart for studies included in the meta-analysis






**Supplementary Material 2. Risk-of-bias summary for included trials**

**A.**

Unique ID	Study ID	D1	D2	D3	D4	D5	Overall	
meta1	Hyo-Soo Kim	+	+	+	+	+	+	+
meta2	Thomas Pilgrim	+	+	+	+	+	+	!
meta3	Juan F Iglesias	!	+	+	+	+	+	-
meta4	Thomas Pilgrim	+	+	+	+	+	+	
meta5	Yao-Jun Zhang	+	+	+	+	!	+	D1 Randomisation process
meta6	Hyun Jong Lee	+	+	+	+	+	+	D2 Deviations from the intended interventions
meta7	Antoinette de Waha	+	!	+	+	!	+	D3 Missing outcome data
meta8	QI ZHANG	!	!	+	+	!	+	D4 Measurement of the outcome
								D5 Selection of the reported result

**B.**

As percentage (intention-to-treat)



**Table 1. The characteristics of the included trails**

Authors	Years	Journal	Study	Center	Country	Follow up	NO.patients	
							BP-DES	DP-DES
<u>Hyo-Soo Kim</u>	<u>2021</u>	<u>Circulation</u>	<u>RCT</u>	<u>multicentre</u>	<u>Korea</u>	<u>12 month</u>	<u>1700</u>	<u>1713</u>
<u>Thomas Pilgrim</u>	<u>2021</u>	<u>JACC</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>24month</u>	<u>649</u>	<u>651</u>
<u>Juan F Iglesias</u>	<u>2019</u>	<u>The Lancet</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>12 month</u>	<u>649</u>	<u>651</u>
<u>Thomas Pilgrim</u>	<u>2016</u>	<u>EuroIntervention</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>12 month</u>	<u>211</u>	<u>196</u>
<u>Yao-Jun Zhang</u>	<u>2015</u>	<u>Heart</u>	<u>RCT</u>	<u>multicentre</u>	<u>Netherlands</u>	<u>60month</u>	<u>280</u>	<u>293</u>
<u>Hyun Jong Lee</u>	<u>2015</u>	<u>International journal of cardiology</u>	<u>RCT</u>	<u>multicentre</u>	<u>Korea</u>	<u>24month</u>	<u>171</u>	<u>536</u>
<u>Antoinette de Waha</u>	<u>2015</u>	<u>EuroIntervention</u>	<u>RCT</u>	<u>multicentre</u>	<u>multicentre</u>	<u>48month</u>	<u>291</u>	<u>206</u>
<u>Qi Zhang</u>	<u>2014</u>	<u>Journal of Interventional Cardiology</u>	<u>RCT</u>	<u>multicentre</u>	<u>China</u>	<u>12 month</u>	<u>596</u>	<u>596</u>



**Table 2. The baseline features of the patients**

Authors	basic characters									
	Age		SEX(MALE)		Body mass index		Hypertension		Diabetes	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim	63.1±11.1	63.0±11.1	1337	1351	25.0±3.2	24.9±3.1	1147	1092	747	789
Juan F Iglesias	62.2±11.8	63.2±11.8	513	477	26.9± 4.3	26.8± 4.3	281	297	73	82
Thomas Pilgrim	61.3±12.4	61.7±12.7	170	151	27.0±4.3	27.0±4.3	102	98	30	27
Yao-Jun Zhang	62.9±11.7	62.8±11.7	215	210	27.5±4.4	27.8±4.6	181	198	55	46
Hyun Jong Lee	64±14.08	63±14.08	128	400	/	/	102	308	82	269
Antoinette de Waha	62.5±12.1	63.1±12.6	214	149	/	/	142	110	56	34
Qi Zhang	63.9±13.1	64.1±12.1	475	467	/	/	360	376	129	113

**Table 2. The baseline features of the patients**

Authors	basic characters									
	Dyslipidemia		smoking		LVEF, %		Stent number per person		Total stent length, mm	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim	1,247	1,280	515	475	58.7±10.4	58.5±10.4	1.7±1.1	1.7±1.0	42.9±31.9	41.7±30.2
Juan F Iglesias	304	302	294	250	49.0 ± 11.0	48.4 ± 11.2	1.37 ± 0.64	1.5 ± 0.66	31.91± 18.21	33.92± 19.76
Thomas Pilgrim	110	101	93	77	49.5±10.9	48.3±11.1	1.42±0.71	1.3±0.71	29.49±17.83	30.52±18.99
Yao-Jun Zhang	152	176	107	115	51.5±10.1	51.4±11.8	2.2±0.5	2.2±0.6	26.6±15	27.9±15.2
Hyun Jong Lee	116	389	65	228	55 (45–65)	52 (43–62)	/	/	/	/
Antoinette de Waha	119	109	120	90	47±10	48±12	/	/	25.9±12.6	27.7±14.2
Qi Zhang	87	76	257	223	50±12	49.0 ± 17.0	/	/	/	/

# BMJ Open

## Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058075.R2
Article Type:	Original research
Date Submitted by the Author:	29-Mar-2022
Complete List of Authors:	Yuan, Haoyong; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials Wu, Zhongshi; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials Lu, Ting; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials Wei, Tingting; Hunan Provincial Maternal and Child Health Care Hospital, Department of Paediatrics Zeng, Yifan; Central South University, Department of Cardiovascular Surgery Liu, Yalin; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials Huang, Can; Central South University, Department of Cardiovascular Surgery; Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Medical management
Keywords:	Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Myocardial infarction < CARDIOLOGY
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.	
726399_Figure_1.tif 726399_Figure_2.tif 726399_Figure_3.tif 726399_Figure_4.tif 726399_Figure_5.tif 726399_Figure_6.tif 726399_Figure_7.tif 726399_Figure_8.tif	

726399\_Figure\_9.tif  
726399\_Figure\_10.tif

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary**  
5  
6 **syndrome: a meta-analysis**  
7  
8

9 Haoyong Yuan, MD<sup>1,2</sup>, Zhongshi Wu, MD<sup>1,2</sup>, Ting Lu, MD<sup>1,2</sup>, Tingting Wei, MD<sup>3</sup>, Yifan Zeng,  
10  
11 MD<sup>1</sup>, Yalin Liu<sup>1,2</sup>, Can Huang, MD<sup>1,2\*</sup>  
12  
13

14  
15 <sup>1</sup>Department of Cardiovascular Surgery, the Second Xiangya Hospital of Central South  
16  
17 University, Changsha, Hunan 410011, China  
18  
19

20  
21 <sup>2</sup>Engineering Laboratory of Hunan Province for Cardiovascular Biomaterials, Changsha,  
22  
23 Hunan 410008, China  
24  
25

26  
27 <sup>3</sup>Department of Paediatrics, Hunan Provincial Maternal and Child Health Care Hospital,  
28  
29 Changsha, Hunan 410008, China  
30  
31

32  
33  
34  
35  
36 **\*Corresponding author:** Can Huang  
37

38  
39 Department of Cardiovascular Surgery, Second Xiangya Hospital, Central South University,  
40  
41 #139 Renmin Road, Changsha, Hunan, 410011, P.R. China  
42  
43

44 Tel: +86 73185292133  
45

46 Fax: +86 73185292133  
47

48 E-mail: huangcan413@csu.edu.cn  
49  
50

51  
52  
53 Word

count:

3001  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** To compare the safety and effectiveness between biodegradable polymer drug-eluting stents (BP-DES) and durable polymer drug-eluting stents (DP-DES) in patients with acute coronary syndrome (ACS)

**Design:** Meta-analysis of randomized controlled trials (RCTs)

**Primary and secondary outcome measures:** Major adverse cardiovascular events (MACEs) were considered the primary endpoint. Efficacy endpoints included target vessel revascularization (TVR) and target lesion revascularization (TLR). Safety endpoints included all-cause death, cardiac death, target vessel myocardial infarction (TVMI), and ST.

**Methods:** We searched PubMed, Medline, Embase, and the Cochrane Controlled Register of Trials (CENTRAL) for comparative studies of BP-DES and DP-DES in patients with ACS from January 2000 to July 2021. Statistical pooling was performed to estimate incidence using a random-effects model with generic inverse-variance weighting. Risk estimates were computed with 95% confidence intervals (CIs).

**Results:** Eight articles with seven RCTs that compared BP-DES and DP-DES in patients with ACS were identified and included in the qualitative and quantitative analyses. There was no difference in the baseline characteristics, except for the number of smoking patients (OR: 1.13, 95% CI: 1.03–1.24;  $p=0.008$ ,  $I^2=29\%$ ), which was significantly lower in the BP-DES group. The meta-analysis demonstrated that MACEs, efficacy endpoints, and safety endpoints were similar between the groups at 1 year. However, the incidence of total stent thrombosis (ST) was significantly different between the BP-DES and DP-DES groups in the follow-up

1  
2  
3  
4 period ( $p=0.0001$ ). Further analysis showed a statistically significant difference in MACEs  
5  
6 (OR: 0.71, 95% CI: 0.57–0.88;  $p=0.002$ ,  $I^2=0\%$ ), TLR (OR: 0.71, 95% CI: 0.51–1.01;  $p=0.05$ ,  
7  
8  $I^2=0\%$ ), TVR (OR: 0.70, 95% CI: 0.52–0.94;  $p=0.002$ ,  $I^2=15\%$ ), total ST incidence (OR: 0.59,  
9  
10 95% CI: 0.46–0.77;  $p=0.0001$ ,  $I^2=48\%$ ), and ST incidence (OR: 0.63, 95% CI: 0.47–0.85;  
11  
12  $p=0.002$ ,  $I^2=0\%$ ) over 2 years.  
13  
14  
15  
16

17 **Conclusion:** This meta-analysis revealed that both stent types demonstrated excellent safety  
18  
19 and efficacy profiles at 12 months. However, a slight increase in MACEs, TLR, TVR, and ST  
20  
21 incidence was observed in the DP-DES group over the 2-year follow-up period, suggesting that  
22  
23 BP-DES may be more favorable when treating patients with ACS.  
24  
25  
26

27  
28 **Keywords:** acute coronary syndrome, biodegradable drug-eluting stent, durable polymer drug-  
29  
30 eluting stent, major adverse cardiac event, stent thrombosis, target lesion revascularization,  
31  
32 target vessel revascularization  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Strengths and limitations of this study

- This meta-analysis included randomized controlled trials with long-term follow-ups.
- The large sample size ensures adequate statistical power to detect even a small effect of interest.
- Heterogeneity among the BP-DES may distort the reported results.
- The differences in the duration of dual antiplatelet therapy may influence clinical outcomes.

For peer review only

## INTRODUCTION

Percutaneous coronary intervention (PCI) is the current standard of care for patients with coronary artery disease, particularly acute coronary syndrome (ACS)<sup>[1, 2]</sup>. Unlike bare-metal stents (BMS), drug-eluting stents (DES) use antiproliferative agents embedded in a polymer coating on the stent's surface, which inhibit neointimal hyperplasia to reduce the risk of restenosis<sup>[3]</sup>. DES have substantially improved clinical outcomes; however, the first-generation durable polymer DES (DP-DES) were known to release sirolimus or paclitaxel, and were associated with similar risks of death and myocardial infarction compared with those of BMS beyond 1 year after implantation<sup>[4]</sup>. Later, the second-generation DP-DES were confirmed to have lower restenosis rates than the first-generation devices and demonstrated reduced rates of stent thrombosis (ST)<sup>[5]</sup>. Recently, very late ST and neoatherosclerosis, with adverse clinical outcomes, have been observed with the second-generation DP-DES, which has improved the biocompatibility of the polymer<sup>[6]</sup>. Late stent failure has been attributed to delayed endothelial healing secondary to a hypersensitivity reaction due to the durable polymer<sup>[7]</sup>.

To address this potential limitation of DP-DES, biodegradable polymer DES (BP-DES) have been developed. Theoretically, BP-DES would lead to a reduction in vascular inflammation and a decreased risk of late stent-related complications due to the advantage of leaving the BMS only after complete drug elution and polymer degradation. BP-DES have been observed to reduce the rate of major adverse cardiac events (MACEs) compared with BMS<sup>[8]</sup> and first-generation DP-DES<sup>[9]</sup>. Studies of patients who underwent PCI revealed that the device-related outcomes were comparable between BP-DES and second-generation DP-DES<sup>[10-13]</sup>. Thus, BP-DES would be expected to reduce the risk of ST-related MACEs beyond

1  
2  
3  
4 the first year compared with that of DP-DES. However, previous studies enrolled a significant  
5  
6 proportion of stable angina patients. ACS confers an increased risk of adverse outcomes due to  
7  
8 plaque characteristics, including culprit lesions, thrombus burden, and persistent inflammation,  
9  
10 compared with stable coronary artery diseases. ACS also increases the risk of delayed arterial  
11  
12 healing and vessel remodeling<sup>[14]</sup>, reflected by higher rates of incomplete stent strut coverage<sup>[15,</sup>  
13  
14  
15  
16  
17 <sup>16]</sup> and malpositioning<sup>[17]</sup>.

18  
19  
20 Recently, many randomized trials have been performed to compare the efficacy and safety  
21  
22 of DP-DES and BP-DES in patients with ACS who underwent PCI. In this meta-analysis, we  
23  
24 aimed to summarize the studies comparing the two polymer technologies in ACS patients and  
25  
26 analyze the safety and effectiveness of these therapeutic options.  
27  
28  
29

## 30 31 **METHODS**

### 32 33 34 *Search strategy and registration*

35  
36  
37 This study was conducted according to the Preferred Reporting Items for Systematic  
38  
39 Reviews and Meta-Analyses (PRISMA) guidelines and was approved by the institutional  
40  
41 review board of the Second Xiangya Hospital, Central South University. The protocol was  
42  
43 registered with PROSPERO (CRD42021253412).  
44  
45  
46

47  
48  
49 Based on the PRISMA statement, PubMed, Medline, Embase, and the Cochrane  
50  
51 Controlled Register of Trials (CENTRAL) databases were searched for comparative studies of  
52  
53 BP-DES and DP-DES that were used in the treatment of patients with ACS who underwent  
54  
55 PCI. The following search terms were used: “BP-DES,” “biodegradable,” “bioabsorbable,”  
56  
57  
58 “bioabsorbable polymer drug-eluting stent,” “biodegradable polymer drug-eluting stent,” “DP-  
59  
60

1  
2  
3  
4 DES,” “durable polymer,” “durable polymer drug-eluting stent,” “acute coronary syndrome,”  
5  
6 “ACS,” “AMI,” “Acute myocardial infarction,” “Non ST segment elevation myocardial  
7  
8 infarction,” “ST segment elevation myocardial infarction,” “NSTEMI,” and “STEMI.” We also  
9  
10 reviewed prior meta-analyses and the reference lists of the original trials and reviewed articles  
11  
12 to identify further studies. Only English language articles published in peer-reviewed journals  
13  
14 from January 2000 to July 2021 were selected. Analyses were conducted by two independent  
15  
16 reviewers.  
17  
18  
19  
20  
21

### 22 23 ***Eligibility criteria***

24  
25  
26 The inclusion criteria for this meta-analysis were as follows: 1) randomized controlled  
27  
28 trials (RCTs) comparing BP-DES and DP-DES in the treatment of patients with ACS who  
29  
30 underwent PCI; 2) data reporting patients’ baseline characteristics, follow-up durations,  
31  
32 outcomes at the primary, safety, and efficacy endpoints; 3) mean follow-up time over 12  
33  
34 months; and 4) full-text articles.  
35  
36  
37  
38  
39

40 The exclusion criteria for the meta-analysis were as follows: 1) duplications of samples  
41  
42 and reports (evaluated by two independent reviewers); 2) case reports/series; and 3) studies  
43  
44 involving data from a national database.  
45  
46  
47

### 48 49 ***Data extraction and outcome measurement***

50  
51 Two authors (Haoyong Yuan and Tingting Wei) systematically screened the titles and  
52  
53 abstracts of publications retrieved using the search strategy to select studies that met the above  
54  
55 inclusion criteria. Any disagreement regarding the eligibility of particular studies was resolved  
56  
57 through discussion and involvement of a third author (Zhongshi Wu), when necessary. First,  
58  
59  
60

1  
2  
3  
4 baseline characteristics, including the name of the first author, year of publication, study design,  
5  
6 country of origin, number of patients, mean age of participants, and mean duration of follow-  
7  
8 up, were gathered from each included article. In addition, data on sex; body mass index; the  
9  
10 presence of hypertension, diabetes, dyslipidemia, chronic kidney disease, peripheral vessel  
11  
12 disease, or smoking; left ventricular ejection fraction (LVEF); number of stents per person; and  
13  
14 total stent length were collected for evaluation of procedure-related risks. MACEs were  
15  
16 considered the primary endpoint. The efficacy endpoints included target vessel  
17  
18 revascularization (TVR) and target lesion revascularization (TLR). In addition, all-cause death,  
19  
20 cardiac death, target vessel myocardial infarction (TVMI), and ST were used as endpoints to  
21  
22 evaluate the safety of BP-DES and DP-DES.  
23  
24  
25  
26  
27  
28  
29

30  
31 The Risk of Bias 2 (RoB2) tool was utilized to assess the quality of RCTs based on  
32  
33 sequence generation; randomized group allocation; concealment; blinding of participants,  
34  
35 personnel, and outcome assessors; incomplete data; selectivity; outcome reporting; and other  
36  
37 sources of bias (Supplementary Material 1)<sup>[18]</sup>.  
38  
39  
40

### 41 ***Data analysis and synthesis***

42  
43  
44  
45 Continuous variables were reported as the mean (standard deviation), and categorical  
46  
47 variables were expressed as numbers. Statistical pooling was performed to estimate incidence,  
48  
49 according to a random-effects model with generic inverse-variance weighting. We computed  
50  
51 risk estimates with 95% confidence intervals (CIs), using RevMan 5.3 (The Cochrane  
52  
53 Collaboration, The NordicCochrane Centre, Copenhagen, Denmark). Hypothesis testing for  
54  
55 superiority was set at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity  
56  
57  
58  
59  
60

1  
2  
3  
4 was set at the two-tailed 0.10 level and was based on the Cochran Q test, with  $I^2$  values of 25%,  
5  
6 50%, and 75% representing mild, moderate, and severe heterogeneity, respectively.  
7  
8

## 9 10 **RESULTS**

### 11 12 13 *Search results*

14  
15  
16 A total of 895 articles, written in English, were identified through the literature search.  
17  
18 After an initial screening of the titles and abstracts, 803 articles were eliminated, as they were  
19  
20 not related to the topic of this study. Following the removal of these articles, 92 clinical studies  
21  
22 and RCTs of the two polymers remained. After reading the full texts, 28 articles about ACS  
23  
24 remained, with 20 articles including chronic and ACS. Finally, eight articles, with seven RCTs,  
25  
26 remained, with 20 articles including chronic and ACS. Finally, eight articles, with seven RCTs,  
27  
28 comparing BP-DES and DP-DES in patients with ACS were identified and included in the  
29  
30 qualitative and quantitative analyses<sup>[19-26]</sup>. The follow-up duration ranged from 1 year to 5 years  
31  
32 (Supplementary Table 1 and Supplementary Material 2).  
33  
34  
35

### 36 37 38 *General features of the trials*

39  
40  
41 A total number of 8089 patients (3898 patients who were treated with BP-DES and  
42  
43 4191 patients who were treated with DP-DES) were included in this analysis. Further  
44  
45 details about the quality of RCTs; total number of patients retrieved from each trial;  
46  
47 publication years; countries of origin of the publications; centers in which the trials were  
48  
49 performed; follow-up durations; risk factors; and primary, efficacy, and safety endpoints  
50  
51 are listed in Supplementary Table 2 and Supplementary Material 2.  
52  
53  
54  
55

### 56 57 58 *Patient characteristics*

1  
2  
3  
4 The baseline features of the patients are summarized in Supplementary Tables 2. The  
5  
6 mean age of the patients who were treated by BP-DES ranged from 61.3 to 64 years, whereas  
7  
8 the mean age of the patients who were treated by DP-DES ranged from 61.7 to 64.1 years. The  
9  
10 proportions of male patients were above 70% in all included trials. There was no difference in  
11  
12 age (mean difference [MD]: 0.14, 95% CI: -0.66–0.38;  $p=0.60$ ,  $I^2=0\%$ ), sex (male) (odds ratio  
13  
14 [OR]: 1.10, 95% CI: 0.99–1.23;  $p=0.07$ ,  $I^2=0\%$ ), hypertension (OR: 1.03, 95% CI: 0.94–1.13;  
15  
16  $p=0.57$ ,  $I^2=37\%$ ), dyslipidemia (OR: 0.92, 95% CI: 0.83–1.02;  $p=0.10$ ,  $I^2=36\%$ ), LVEF (MD:  
17  
18 0.00, 95% CI: 0.00–0.01;  $p=0.12$ ,  $I^2=12\%$ ), body mass index (MD: 0.07, 95% CI: -0.11 to 0.25;  
19  
20  $p=0.44$ ,  $I^2=0\%$ ), diabetes (OR: 0.92, 95% CI: 0.83–1.02;  $p=0.13$ ,  $I^2=21\%$ ), total stent length  
21  
22 (MD: -0.72, 95% CI: -2.30 to -0.85;  $p=0.37$ ,  $I^2=40\%$ ), and in the number of stents per person  
23  
24 (MD: -0.00, 95% CI: -0.05 to 0.04;  $p=0.84$ ,  $I^2=0\%$ ) among patients who were implanted with  
25  
26 BP-DES or DP-DES. The meta-analysis demonstrated that the number of smoking patients  
27  
28 (OR: 1.13, 95% CI: 1.03–1.24;  $p=0.008$ ,  $I^2=29\%$ ) was significantly lower in the BP-DES group  
29  
30 than that in the DP-DES group (Figure 1-3).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 ***Primary endpoint: MACEs reported during follow-up periods of 1–5 years, 1 year, and over***  
42  
43 ***2 years***  
44  
45  
46

47 MACEs, including all-cause death, recurrent MI, or any coronary repeat revascularization  
48  
49 involving TLR, TVR, and non-TVR, were considered to be the primary endpoint of the trials.  
50  
51 A meta-analysis indicated no statistically significant difference in the MACEs in a follow-up  
52  
53 period ranging from 1 to 5 years between the two groups (OR: 0.87, 95% CI: 0.75–1.01;  $p=0.07$ ,  
54  
55  $I^2=50\%$ ). Of the five studies that published 1-year outcomes, MACEs were not significantly  
56  
57 different between the BP-DES and DP-DES groups (OR: 0.97, 95% CI: 0.81–1.16;  $p=0.74$ ,  
58  
59  
60

1  
2  
3  
4  $I^2=44\%$ ). However, MACEs with follow-up periods of over 2 years were significantly lower  
5  
6 in the BP-DES group (OR: 0.71, 95% CI: 0.57–0.88;  $p=0.002$ ,  $I^2=0\%$ ) (Figure 4).  
7  
8

9  
10 ***Efficacy endpoint: TVR and TLR reported during follow-up periods of 1–5 years, 1 year,***  
11  
12 ***and over 2 years***  
13  
14

15  
16 TLR and TVR were considered the efficacy endpoints of the trials. The meta-analysis  
17  
18 indicated no statistically significant difference in TLR in the follow-up periods ranging from 1  
19  
20 to 5 years between the two groups (OR: 0.78, 95% CI: 0.61–1.00;  $p=0.05$ ,  $I^2=48\%$ ). Among  
21  
22 the five studies that published 1-year data, TLR was not significantly different between the BP-  
23  
24 DES and DP-DES groups (OR: 0.72, 95% CI: 0.40–1.31;  $p=0.29$ ,  $I^2=65\%$ ). The meta-analysis  
25  
26 indicated no statistically significant difference in TVR in the follow-up periods ranging from  
27  
28 1 to 5 years (OR: 1.01, 95% CI: 0.79–1.28;  $p=0.96$ ,  $I^2=46\%$ ) or in the three publications with  
29  
30 1-year follow-up periods (OR: 0.98, 95% CI: 0.40–2.38;  $p=0.96$ ,  $I^2=76\%$ ). However, the  
31  
32 difference in TLR was statistically significant in four RCT studies with follow-up periods of  
33  
34 over 2 years (OR: 0.71, 95% CI: 0.51–1.01;  $p=0.05$ ,  $I^2=0\%$ ), and the difference in TVR was  
35  
36 also statistically significant in three RCT studies with follow-up periods of over 2 years (OR:  
37  
38 0.70, 95% CI: 0.52–0.94;  $p=0.002$ ,  $I^2=15\%$ ), with values much lower in the BP-DES group  
39  
40 (Figures 5 and 6).  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 ***Safety endpoint: All-cause death, cardiac-related death, target vessel myocardial infarction,***  
51  
52 ***and stent thrombosis over follow-up periods of 1–5 years, 1 year, and over 2 years***  
53  
54  
55

56 All-cause death, cardiac-related death, TVMI, and ST were considered the efficacy  
57  
58 endpoints. The meta-analysis indicated no statistically significant difference between the two  
59  
60



1  
2  
3  
4 groups in all-cause death (OR: 0.88, 95% CI: 0.72–1.07;  $p=0.20$ ,  $I^2=0\%$ ), cardiac-related death  
5  
6 (OR: 0.89, 95% CI: 0.71–1.12;  $p=0.32$ ,  $I^2=20\%$ ), and TVMI (OR: 0.73, 95% CI: 0.53–1.01;  
7  
8  $p=0.05$ ,  $I^2=0\%$ ) over a follow-up period ranging from 1 to 5 years. Of the five studies that  
9  
10 published 1-year data, all-cause death, cardiac-related death, and TVMI were also not  
11  
12 significantly different between the BP-DES and DP-DES groups ([all-cause death, OR: 0.91,  
13  
14 95% CI: 0.71–1.15;  $p=0.42$ ,  $I^2=0\%$ ], [cardiac-related death, OR: 0.96, 95% CI: 0.74–1.26;  
15  
16  $p=0.79$ ,  $I^2=35\%$ ], and [TVMI, OR: 0.73, 95% CI: 0.53–1.01;  $p=0.05$ ,  $I^2=0\%$ ]). In the five  
17  
18 studies with follow-up periods of over 2 years, similar findings were observed for the all-cause  
19  
20 cardiac death, cardiac-related death, and TVMI ([all-cause death, OR: 0.85, 95% CI: 0.64–1.12;  
21  
22  $p=0.25$ ,  $I^2=0\%$ ], [cardiac-related death, OR: 0.77, 95% CI: 0.56–1.17;  $p=0.12$ ,  $I^2=0\%$ ], and  
23  
24 [TVMI, OR: 0.79, 95% CI: 0.51–1.22;  $p=0.28$ ,  $I^2=0\%$ ]) (Figures 7–9). However, the total ST  
25  
26 incidence, including the definite ST, probable ST, and definite or probable ST incidence, was  
27  
28 significantly different between the BP-DES and DP-DES groups during the follow-up  
29  
30 period (OR: 0.59, 95% CI: 0.46–0.77;  $p=0.0001$ ,  $I^2=48\%$ ). Further analysis revealed no  
31  
32 difference in total ST for the 1-year follow-up (OR: 0.61, 95% CI: 0.32–1.15;  $P=0.13$ ,  
33  
34  $I^2=72\%$ ), while the meta-analysis indicated a statistically significant difference in the total ST  
35  
36 for the follow-up periods of over 2 years (OR: 0.63, 95% CI: 0.47–0.85;  $p=0.002$ ,  $I^2=0\%$ )  
37  
38 (Figure 10).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 51 **DISCUSSION**

52  
53  
54 The choice of stent in patients undergoing PCI for ACS is debated. Coronary intervention  
55  
56 with second-generation DP-DES generally reduces the need for revascularization and improves  
57  
58 mortality compared with BMS and first-generation DP-DES. Furthermore, the risk of late ST  
59  
60

1  
2  
3  
4 with DP-DES tends to off-set these benefits, as seen in registries and clinical trials comparing  
5  
6 DP-DES to BMS<sup>[15, 27]</sup>. BP-DES was designed to leave only the BMS behind once the polymer  
7  
8 completely bio-degraded after drug elution and may represent an attractive solution for patients  
9  
10 with ACS<sup>[28]</sup>. Prior meta-analyses have compared the clinical outcomes among BMS, DP-DES,  
11  
12 and BP-DES in patients with stable coronary artery disease, but no previous meta-analysis of  
13  
14 RCTs and prospective trials directly compared clinical outcomes between BP-DES and DP-  
15  
16 DES for the treatment of ACS. To our knowledge, this meta-analysis exclusively compared  
17  
18 BP-DES to DP-DES. It included seven trials representing 8089 patients with relatively long  
19  
20 follow-up durations, ranging from 1 year to 5 years. BP-DES have been hypothesized to offer  
21  
22 improved outcomes, mainly in the long term; however, several prior meta-analyses have  
23  
24 demonstrated different outcomes with BP-DES compared with DP-DES in patients undergoing  
25  
26 PCI. Bangalore et al. observed that BP-DES were associated with higher mortality than DP-  
27  
28 DES beyond 1 year of follow-up<sup>[29]</sup>. El-Hayek et al. demonstrated no significant difference in  
29  
30 mortality between these stent types <sup>[6]</sup>. In our study, there were no significant differences in  
31  
32 MACEs, all-cause death, cardiac-related death, TVMI, TVR, or TLR at a follow-up period of  
33  
34 1 year and no significant differences in all-cause death, cardiac death, or TVMI at a follow-up  
35  
36 period of over 2 years. However, at a follow-up of over 2 years, MACEs, TVR, and TLR were  
37  
38 significantly lower in the BP group than those in the DP group. Pilgrim et al. observed higher  
39  
40 all-cause mortality among patients treated with BP-DES than with DP-DES in the  
41  
42 BIOSCIENCE trial; they also observed comparable all-cause mortality rates among patients  
43  
44 treated with BP-DES and DP-DES in the BIOSTEMI trial with a 2-year follow-up<sup>[6]</sup>. Mario  
45  
46 Iannaccone et al. observed that BP-DES might decrease the risk of ischemic events in selected  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 high-risk subgroups of patients, although the two DES stents share the same safety factors for  
5  
6 patients in high-anatomical-risk settings like left main (LM) disease<sup>[30]</sup>. Together, these  
7  
8 findings suggest that BP-DES share similar outcomes in terms of MACEs (all-cause death,  
9  
10 cardiac-related death, TVMI, TVR, and TLR) during a 1-year follow-up and might show  
11  
12 significantly improved clinical outcomes over a 2-year follow-up.  
13  
14  
15  
16

17 ST is defined as a thrombotic occlusion of a coronary stent<sup>[31]</sup> and is a major complication.  
18  
19 The risk of ST, particularly late ST (occurring beyond 30 days), remains one of the major  
20  
21 concerns limiting the use of DES in the treatment of ACS<sup>[32]</sup>. Early-generation DP-DES were  
22  
23 associated with increased rates of very late (>1 year) ST compared with BMS. It was  
24  
25 hypothesized that the mechanism underlying late ST with first DP-DES in ACS was related to  
26  
27 adverse reactions with the durable polymer<sup>[33]</sup>, and the use of more biocompatible polymers  
28  
29 has been associated with a reduction in ST in high-risk patients<sup>[9]</sup>. In the LEADERS trial, the  
30  
31 rate of very late ST was lower with the use of the BP-DES than that with DP-DES<sup>[34]</sup>. Our data  
32  
33 demonstrated that both BP-DES and DP-DES have similar risks of ST beyond 1 year. However,  
34  
35 BP-DES are associated with a significantly reduced risk of ST at a follow-up of over 2 years  
36  
37 compared with DP-DES (OR: 0.64, 95% CI: 0.46–0.88;  $p=0.006$ ,  $I^2=0\%$ ). In contrast, Kim et  
38  
39 al. observed that the incidence of ST by groups demonstrated numerically lower rates in the  
40  
41 DP-DES group (0.1%) than those in the BP-DES group and that all late ST cases occurred in  
42  
43 those receiving thick-strut BP-DES stents. They proposed that no meaningful differences in  
44  
45 terms of ST could be identified between the different polymer technologies by intravascular  
46  
47 imaging and that the association of polymer technology and the risk of the ST was difficult to  
48  
49 prove<sup>[20, 35, 36]</sup>. Therefore, it may be hypothesized that BP-DES result in improved arterial  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 healing, which not only minimizes the risk of ST, but also improves the long-term durability  
5  
6 of the antirestenotic efficacy in the long term, although the two groups have a similar risk of  
7  
8 ST beyond 1 year.  
9  
10

## 11 **Limitations**

12  
13  
14  
15 The present study had several limitations. First, this study included RCTs and shares the  
16  
17 limitations of original studies. Second, BP-DES are a heterogeneous group of stents, differing  
18  
19 in stent platform thickness, time to complete degradation of the polymer, and drug-elution  
20  
21 kinetics. DP-DES is an equally heterogeneous group. Innaccone et al. observed that lower strut  
22  
23 thickness would have a positive clinical outcome, thereby reducing stent thrombosis and target  
24  
25 lesion revascularizations<sup>[37]</sup>. We were unable to match the stents with regards to the strut  
26  
27 thickness. Consequently, the reported results may not be generalizable to all stents from the  
28  
29 respective group. Third, over 6 months of dual antiplatelet therapy (DAPT) was provided to  
30  
31 the patients in our study, including those in RCTs. D'Ascenzo et al. observed a similar rate of  
32  
33 MACEs between durable and biodegradable polymers, irrespective of DAPT length, and the  
34  
35 DAPT duration seems to partially impact the risk of adverse events of different types of stents  
36  
37 during follow-up<sup>[38]</sup>. Thus, we remain concerned that the duration differences of DAPT may  
38  
39 influence the clinical outcomes.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **CONCLUSION**

51  
52  
53 In this meta-analysis comparing BP-DES to DP-DES in ACS patients who underwent PCI,  
54  
55 the data indicated that both polymer types demonstrated excellent safety and efficacy profiles  
56  
57 at 1 year. There was a slightly increased incidence of MACEs, TLR, TVR, and ST in the DP-  
58  
59  
60

1  
2  
3  
4 DES group in the follow-up period of over 2 years, suggesting that BP-DES may be more  
5  
6 favorable for treating patients with ACS. These findings should be confirmed by long-term  
7  
8 follow-ups in RCT trials.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 **Data availability statement**  
59  
60

1  
2  
3  
4 No additional data is available.  
5  
6

### 7 **Patient and public involvement**

8  
9

10 We did not require patient and public involvement, as this is a meta-analysis, and no new  
11 patients were enrolled in the study.  
12  
13

### 14 **Ethics approval**

15  
16

17 This study was conducted according to the Preferred Reporting Items for Systematic Reviews  
18 and Meta-Analyses (PRISMA) guidelines, and the protocol was registered with PROSPERO  
19 (CRD42021253412). This study was approved by the institutional review board of the Second  
20 Xiangya Hospital of Central South University.  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Funding**

30  
31

32 This work was supported by the Hunan Provincial Natural Science Foundation of China (grant  
33 number 2020JJ4787).  
34  
35  
36  
37  
38  
39

### 40 **Competing interests And Acknowledgements**

41  
42

43 The authors report no conflicts of interest in this work. We would like to thank Editage  
44 (www.editage.com) for English language editing  
45  
46  
47  
48

### 49 **Author contributions**

50  
51

52 Can Huang, Zhongshi Wu, and Haoyong Yuan developed the idea of the study, participated in  
53 its design and coordination, and helped draft the manuscript. Ting Lu and Tingting Wei  
54 contributed to the acquisition and interpretation of data. Yifan Zeng and Yalin Liu provided a  
55 critical review and substantially revised the manuscript. All authors read and approved the final  
56  
57  
58  
59  
60

1  
2  
3  
4 manuscript.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

## 57 **References**

58 [1] Mehta S R, Cannon C P, Fox K A, et al. Routine vs selective invasive strategies in  
59  
60

1  
2  
3 patients with acute coronary syndromes: a collaborative meta-analysis of randomized  
4 trials[J]. JAMA, 2005,293(23):2908-2917.

5  
6 [2] Fox K A, Clayton T C, Damman P, et al. Long-term outcome of a routine versus  
7 selective invasive strategy in patients with non-ST-segment elevation acute coronary  
8 syndrome a meta-analysis of individual patient data[J]. J Am Coll Cardiol, 2010,55(22):2435-  
9 2445.

10  
11 [3] Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from  
12 preclinical and pathology studies[J]. Nat Rev Cardiol, 2020,17(1):37-51.

13  
14 [4] Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of  
15 tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute  
16 myocardial infarction: the MULTISTRATEGY randomized trial[J]. JAMA,  
17 2008,299(15):1788-1799.

18  
19 [5] Raber L, Magro M, Stefanini G G, et al. Very late coronary stent thrombosis of a newer-  
20 generation everolimus-eluting stent compared with early-generation drug-eluting stents: a  
21 prospective cohort study[J]. Circulation, 2012,125(9):1110-1121.

22  
23 [6] El-Hayek G, Bangalore S, Casso D A, et al. Meta-Analysis of Randomized Clinical  
24 Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable  
25 Polymer Drug-Eluting Stents[J]. JACC Cardiovasc Interv, 2017,10(5):462-473.

26  
27 [7] Finn A V, Nakazawa G, Kolodgie F D, et al. Temporal course of neointimal formation  
28 after drug-eluting stent placement: is our understanding of restenosis changing?[J]. JACC  
29 Cardiovasc Interv, 2009,2(4):300-302.

30  
31 [8] Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with  
32 biodegradable polymer vs bare-metal stents on cardiovascular events among patients with  
33 acute myocardial infarction: the COMFORTABLE AMI randomized trial[J]. JAMA,  
34 2012,308(8):777-787.

35  
36 [9] Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent  
37 in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a  
38 randomised controlled trial[J]. Lancet, 2012,380(9852):1482-1490.

39  
40 [10] von Birgelen C, Kok M M, van der Heijden L C, et al. Very thin strut biodegradable  
41 polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-  
42 eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm,  
43 randomised, non-inferiority trial[J]. Lancet, 2016,388(10060):2607-2617.

44  
45 [11] Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting  
46 stent versus durable polymer everolimus-eluting stent for percutaneous coronary  
47 revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial[J]. Lancet,  
48 2014,384(9960):2111-2122.



- 1  
2  
3 [12]Smits P C, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting  
4 stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised,  
5 controlled, non-inferiority trial[J]. *Lancet*, 2013,381(9867):651-660.  
6  
7  
8 [13]Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting  
9 stent versus durable polymer everolimus-eluting stent: a randomized, controlled,  
10 noninferiority trial[J]. *J Am Coll Cardiol*, 2013,62(3):181-190.  
11  
12  
13 [14]Pilgrim T, Piccolo R, Heg D, et al. Biodegradable polymer sirolimus-eluting stents  
14 versus durable polymer everolimus-eluting stents for primary percutaneous coronary  
15 revascularisation of acute myocardial infarction[J]. *EuroIntervention*, 2016,12(11):e1343-  
16 e1354.  
17  
18  
19 [15]Gonzalo N, Barlis P, Serruys P W, et al. Incomplete stent apposition and delayed tissue  
20 coverage are more frequent in drug-eluting stents implanted during primary percutaneous  
21 coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting  
22 stents implanted for stable/unstable angina: insights from optical coherence tomography[J].  
23 *JACC Cardiovasc Interv*, 2009,2(5):445-452.  
24  
25  
26 [16]Raber L, Baumgartner S, Garcia-Garcia H M, et al. Long-term vascular healing in  
27 response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography  
28 study[J]. *JACC Cardiovasc Interv*, 2012,5(9):946-957.  
29  
30  
31 [17]Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings  
32 with histopathological analysis of thrombus aspirates in patients with very late drug-eluting  
33 stent thrombosis[J]. *Circulation*, 2009,120(5):391-399.  
34  
35  
36 [18]Sterne J A, Hernan M A, Reeves B C, et al. ROBINS-I: a tool for assessing risk of bias in  
37 non-randomised studies of interventions[J]. *BMJ*, 2016,355:i4919.  
38  
39  
40 [19]de Waha A, King L A, Stefanini G G, et al. Long-term outcomes of biodegradable versus  
41 durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial  
42 infarction: a pooled analysis of individual patient data from three randomised trials[J].  
43 *EuroIntervention*, 2015,10(12):1425-1431.  
44  
45  
46 [20]Kim H S, Kang J, Hwang D, et al. Durable Polymer Versus Biodegradable Polymer  
47 Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute  
48 Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial[J]. *Circulation*,  
49 2021,143(11):1081-1091.  
50  
51  
52 [21]Lee H J, Park T K, Song Y B, et al. Biodegradable polymer biolimus-eluting stent versus  
53 durable polymer everolimus-eluting stent in patients with acute myocardial infarction[J]. *Int J*  
54 *Cardiol*, 2015,183:190-197.  
55  
56  
57 [22]Iglesias J F, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents  
58 versus durable polymer everolimus-eluting stents in patients with ST-segment elevation  
59  
60

1  
2  
3 myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority  
4 trial[J]. *Lancet*, 2019,394(10205):1243-1253.

5  
6 [23]Zhang Q, Qiu J P, Kirtane A J, et al. Comparison of biodegradable polymer versus  
7 durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial  
8 infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE  
9 study[J]. *J Interv Cardiol*, 2014,27(2):131-141.

10  
11 [24]Pilgrim T, Piccolo R, Heg D, et al. Biodegradable polymer sirolimus-eluting stents  
12 versus durable polymer everolimus-eluting stents for primary percutaneous coronary  
13 revascularisation of acute myocardial infarction[J]. *EuroIntervention*, 2016,12(11):e1343-  
14 e1354.

15  
16 [25]Zhang Y J, Iqbal J, Windecker S, et al. Biolimus-eluting stent with biodegradable  
17 polymer improves clinical outcomes in patients with acute myocardial infarction[J]. *Heart*,  
18 2015,101(4):271-278.

19  
20 [26]Pilgrim T, Muller O, Heg D, et al. Biodegradable- Versus Durable-Polymer Drug-Eluting  
21 Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial[J]. *JACC Cardiovasc*  
22 *Interv*, 2021,14(6):639-648.

23  
24 [27]Guagliumi G, Costa M A, Sirbu V, et al. Strut coverage and late malapposition with  
25 paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction:  
26 optical coherence tomography substudy of the Harmonizing Outcomes with  
27 Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial[J].  
28 *Circulation*, 2011,123(3):274-281.

29  
30 [28]Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from  
31 preclinical and pathology studies[J]. *Nat Rev Cardiol*, 2020,17(1):37-51.

32  
33 [29]Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting  
34 stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed  
35 treatment comparison meta-analysis[J]. *BMJ*, 2013,347:f6625.

36  
37 [30]Iannaccone M, Barbero U, De Benedictis M, et al. Comparison of bioresorbable vs  
38 durable polymer drug-eluting stents in unprotected left main (from the RAIN-  
39 CARDIOGROUP VII Study)[J]. *BMC Cardiovasc Disord*, 2020,20(1):225.

40  
41 [31]Modi K, Soos M P, Mahajan K. Stent Thrombosis[J]. 2022.

42  
43 [32]Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of  
44 sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large  
45 two-institutional cohort study[J]. *Lancet*, 2007,369(9562):667-678.

46  
47 [33]Siqueira D A, Abizaid A A, Costa J R, et al. Late incomplete apposition after drug-  
48 eluting stent implantation: incidence and potential for adverse clinical outcomes[J]. *Eur Heart*  
49 *J*, 2007,28(11):1304-1309.

1  
2  
3 [34]Stefanini G G, Byrne R A, Serruys P W, et al. Biodegradable polymer drug-eluting stents  
4 reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary  
5 intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-  
6 TEST 4, and LEADERS randomized trials[J]. *Eur Heart J*, 2012,33(10):1214-1222.  
7  
8

9 [35]Guagliumi G, Shimamura K, Sirbu V, et al. Temporal course of vascular healing and  
10 neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting  
11 stents[J]. *Eur Heart J*, 2018,39(26):2448-2456.  
12  
13

14 [36]Kuramitsu S, Kazuno Y, Sonoda S, et al. Vascular response to bioresorbable polymer  
15 sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-  
16 up: an optical coherence tomography sub-study from the CENTURY II trial[J]. *Eur Heart J*  
17 *Cardiovasc Imaging*, 2016,17(1):34-40.  
18  
19

20 [37]Iannaccone M, Gatti P, Barbero U, et al. Impact of strut thickness and number of crown  
21 and connectors on clinical outcomes on patients treated with second-generation drug eluting  
22 stent[J]. *Catheter Cardiovasc Interv*, 2020,96(7):1417-1422.  
23  
24

25 [38]D'Ascenzo F, Iannaccone M, Saint-Hilary G, et al. Impact of design of coronary stents  
26 and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-  
27 analysis of 64 randomized controlled trials and 102 735 patients[J]. *Eur Heart J*,  
28 2017,38(42):3160-3172.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

## 57 SUPPLEMENTARY TABLE LEGENDS

58  
59  
60

1  
2  
3  
4 Table 1. The characteristics of the included trials  
5

6  
7 Table 2. The baseline features of the patients  
8  
9

## 10 **FIGURE LEGENDS**

11  
12  
13  
14 Figure 1. Baseline characteristics and stent information of patients with acute coronary  
15  
16 syndrome  
17

18  
19  
20 Figure 2. Baseline characteristics and stent information of patients with acute coronary  
21  
22 syndrome  
23

24  
25  
26 Figure 3. Baseline characteristics and stent information of patients with acute coronary  
27  
28 syndrome  
29

30  
31 Figure 4. Primary endpoint: major adverse cardiac events  
32

33  
34 Figure 5. Target vessel revascularization  
35

36  
37 Figure 6. Target lesion revascularization  
38

39  
40  
41 Figure 7. All-cause death  
42

43  
44 Figure 8. Cardiac-related death  
45

46  
47 Figure 9. Target vessel myocardial infarction  
48

49  
50  
51 Figure 10. Stent thrombosis  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary Material 2: search strategie and PRISMA flow chart for included studies

### A. Search strategie

#### 1. Pubmed (N=688)

**Search date:** from January 2000 to July 2021

**Search terms:**

1#. ("BP-DES"[MeSH Terms] OR "BP-DES"[All Fields] OR "biodegradable "[All Fields] OR "bioabsorbable "[All Fields] OR "bioabsorbable polymer drug-eluting stent"[All Fields] OR "biodegradable polymer drug-eluting stent"[All Fields]) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

2#. ("DP-DES"[All Fields] OR "DP-DES"[MeSH Terms] OR "durable polymer"[All Fields] OR "durable polymer drug-eluting stent"[All Fields] ) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

3#. ("BP-DES"[MeSH Terms] OR "BP-DES"[All Fields] OR "biodegradable "[All Fields] OR "bioabsorbable "[All Fields] OR "bioabsorbable polymer drug-eluting stent"[All Fields] OR "biodegradable polymer drug-eluting stent"[All Fields]) and ("DP-DES"[All Fields] OR "DP-DES"[MeSH Terms] OR "durable polymer"[All Fields] OR "durable polymer drug-eluting stent"[All Fields] ) AND ("acute coronary syndrome"[All Fields] OR "ACS"[All Fields] OR "AMI"[All Fields] OR "Acute myocardial infarction"[All Fields] OR "Non ST segment elevation myocardial infarction"[All Fields] OR "ST segment elevation myocardial infarction"[All Fields] OR "NSTEMI"[All Fields] OR "STEMI"[All Fields])

#### 2. OVID (N=207, EMBS=134, MEDLINE=54, Controlled Register of Trials=19)

**Search date:** from January 2000 to July 2021


**Search terms:**

1#.( "BP-DES" OR "bioabsorbable polymer drug-eluting stent" OR "biodegradable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

2#.( "DP-DES" OR "durable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

3#.( "BP-DES" OR "bioabsorbable polymer drug-eluting stent" OR "biodegradable polymer drug-eluting stent" ) and ( "DP-DES" OR "durable polymer drug-eluting stent" ) and ( "acute coronary syndrome" OR "ACS" OR "AMI" OR "Acute myocardial infarction" OR "Non ST segment elevation myocardial infarction" OR "ST segment elevation myocardial infarction" OR "NSTEMI" OR "STEMI" )

#### B. PRISMA flow chart for studies included in the meta-analysis



**Table 1. The characteristics of the included trails**

Authors	Years	Journal	Study	Center	Country	Follow up	NO.patients	
							BP-DES	DP-DES
<u>Hyo-Soo Kim</u>	<u>2021</u>	<u>Circulation</u>	<u>RCT</u>	<u>multicentre</u>	<u>Korea</u>	<u>12 month</u>	<u>1700</u>	<u>1713</u>
<u>Thomas Pilgrim</u>	<u>2021</u>	<u>JACC</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>24month</u>	<u>649</u>	<u>651</u>
<u>Juan F Iglesias</u>	<u>2019</u>	<u>The Lancet</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>12 month</u>	<u>649</u>	<u>651</u>
<u>Thomas Pilgrim</u>	<u>2016</u>	<u>EuroIntervention</u>	<u>RCT</u>	<u>multicentre</u>	<u>Switzerland</u>	<u>12 month</u>	<u>211</u>	<u>196</u>
<u>Yao-Jun Zhang</u>	<u>2015</u>	<u>Heart</u>	<u>RCT</u>	<u>multicentre</u>	<u>Netherlands</u>	<u>60month</u>	<u>280</u>	<u>293</u>
<u>Hyun Jong Lee</u>	<u>2015</u>	<u>International journal of cardiology</u>	<u>RCT</u>	<u>multicentre</u>	<u>Korea</u>	<u>24month</u>	<u>171</u>	<u>536</u>
<u>Antoinette de Waha</u>	<u>2015</u>	<u>EuroIntervention</u>	<u>RCT</u>	<u>multicentre</u>	<u>multicentre</u>	<u>48month</u>	<u>291</u>	<u>206</u>
<u>Qi Zhang</u>	<u>2014</u>	<u>Journal of Interventional Cardiology</u>	<u>RCT</u>	<u>multicentre</u>	<u>China</u>	<u>12 month</u>	<u>596</u>	<u>596</u>

**Table 2. The baseline features of the patients**

Authors	basic characters									
	Age		SEX(MALE)		Body mass index		Hypertension		Diabetes	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim	63.1±11.1	63.0±11.1	1337	1351	25.0±3.2	24.9±3.1	1147	1092	747	789
Juan F Iglesias	62.2±11.8	63.2±11.8	513	477	26.9± 4.3	26.8± 4.3	281	297	73	82
Thomas Pilgrim	61.3±12.4	61.7±12.7	170	151	27.0±4.3	27.0±4.3	102	98	30	27
Yao-Jun Zhang	62.9±11.7	62.8±11.7	215	210	27.5±4.4	27.8±4.6	181	198	55	46
Hyun Jong Lee	64±14.08	63±14.08	128	400	/	/	102	308	82	269
Antoinette de Waha	62.5±12.1	63.1±12.6	214	149	/	/	142	110	56	34
Qi Zhang	63.9±13.1	64.1±12.1	475	467	/	/	360	376	129	113



**Table 2. The baseline features of the patients**

Authors	basic characters									
	Dyslipidemia		smoking		LVEF, %		Stent number per person		Total stent length, mm	
	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES	BP-DES	DP-DES
Hyo-Soo Kim	1,247	1,280	515	475	58.7±10.4	58.5±10.4	1.7±1.1	1.7±1.0	42.9±31.9	41.7±30.2
Juan F Iglesias	304	302	294	250	49.0 ± 11.0	48.4 ± 11.2	1.37 ± 0.64	1.5 ± 0.66	31.91± 18.21	33.92± 19.76
Thomas Pilgrim	110	101	93	77	49.5±10.9	48.3±11.1	1.42±0.71	1.3±0.71	29.49±17.83	30.52±18.99
Yao-Jun Zhang	152	176	107	115	51.5±10.1	51.4±11.8	2.2±0.5	2.2±0.6	26.6±15	27.9±15.2
Hyun Jong Lee	116	389	65	228	55 (45–65)	52 (43–62)	/	/	/	/
Antoinette de Waha	119	109	120	90	47±10	48±12	/	/	25.9±12.6	27.7±14.2
Qi Zhang	87	76	257	223	50±12	49.0 ± 17.0	/	/	/	/

**Supplementary Material 2. Risk-of-bias summary for included trials**

**A.**

Unique ID	Study ID	D1	D2	D3	D4	D5	Overall	
meta1	Hyo-Soo Kim	+	+	+	+	+	+	+
meta2	Thomas Pilgrim	+	+	+	+	+	+	!
meta3	Juan F Iglesias	!	+	+	+	+	+	-
meta4	Thomas Pilgrim	+	+	+	+	+	+	
meta5	Yao-Jun Zhang	+	+	+	+	!	+	D1 Randomisation process
meta6	Hyun Jong Lee	+	+	+	+	+	+	D2 Deviations from the intended interventions
meta7	Antoinette de Waha	+	!	+	+	!	+	D3 Missing outcome data
meta8	QI ZHANG	!	!	+	+	!	+	D4 Measurement of the outcome
								D5 Selection of the reported result

**B.**

As percentage (intention-to-treat)

